PROMIS NEUROSCIENCES INC.

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14 (a) of the

Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant ☒ Filed by a party other than the Registrant ☐

Check the appropriate box:

☐	Preliminary Proxy Statement

☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2))

☒	Definitive Proxy Statement

☐	Definitive Additional Materials

☐	Soliciting Material under §240.14a-12

PROMIS NEUROSCIENCES INC.

(Name of Registrant as Specified in its Charter)

Not applicable.

(Name of Person (s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒	No fee required.

☐	Fee paid previously with preliminary materials.

☐	Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6 (i) (1) and 0-11.

Table of Contents

PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

TORONTO, ONTARIO, CANADA M4S 3E2

(416) 847-6898

NOTICE OF 2026 ANNUAL MEETING OF

SHAREHOLDERS

To Be Held on May 20, 2026

To Our Shareholders:

You are cordially invited to attend the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of ProMIS Neurosciences Inc. (the “Company”). This year’s Annual Meeting will be a virtual meeting, which will be conducted via live webcast on Wednesday, May 20, 2026 at 10:30 a.m., Eastern Time. You may attend the meeting virtually by registering at http://www.virtualshareholdermeeting.com/PMN2026, where you will be able to vote electronically and submit questions, subject to the registration procedures set forth below.

Only shareholders who owned our common shares, no par value (“Common Shares”) at the close of business on March 23, 2026 can vote at the Annual Meeting or any adjournment that may take place. At the Annual Meeting, the shareholders will consider and vote on the following matters:

To elect seven directors, each to serve until the next annual meeting of shareholders and until his or her respective successors is duly elected and qualified, or such director’s earlier death, resignation, or removal;

To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

To approve an amendment to the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan; and

To transact any other business that may properly come before the Annual Meeting or any adjournment thereof.

In addition, at our Annual Meeting, the shareholders will receive (but not vote on) the consolidated financial statements of the Company for the fiscal year ended December 31, 2025, including the auditor’s report therein.

As noted above, our Annual Meeting will be a “virtual meeting” of shareholders, which will be conducted exclusively via the Internet. There will not be a physical meeting location, and shareholders will not be able to attend the Annual Meeting in person. You may attend the Annual Meeting via the Internet, vote your shares during the Annual Meeting, and submit questions before the Annual Meeting by registering at http://www.virtualshareholdermeeting.com/PMN2026.

In order to attend the meeting online, vote your shares electronically during the meeting and submit questions before the meeting, registered shareholders must register in advance at http://www.virtualshareholdermeeting.com/PMN2026 using the control number located in the box in the upper right-hand corner of your proxy card or in the body of the e-mail notification you received. Most of our shareholders do not hold shares directly in their own name but instead are non-registered shareholders who beneficially own shares that are held by an intermediary, such as their bank, trust company, securities broker, trustee, or other nominee. If you are a non-registered shareholder and wish to attend the meeting online, vote your shares electronically during the meeting and submit questions before the meeting, you must appoint yourself as your proxyholder following the procedures provided to you by your intermediary and register in advance at http://www.virtualshareholdermeeting.com/PMN2026. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you to access the meeting and will permit you to submit questions. Further information about how to attend the Annual Meeting online, vote your shares and submit questions is included in the accompanying proxy statement.

You can find more information, including the nominees for director, in the proxy statement for the Annual Meeting, which is attached and also available for viewing, printing and downloading at www.proxyvote.com. As outlined in the

Table of Contents

attached proxy statement, the board of directors recommends that you vote in favor of each director nominee in Proposal 1 and in favor of Proposals 2 and 3.

Instead of mailing a paper copy of our proxy materials to all of our shareholders, we are providing access to our proxy materials via the Internet under Canadian and U.S. securities laws. As a result, we are sending to our shareholders a Notice of Internet Availability of Proxy Materials (the “Notice”), instead of a paper copy of this proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”). This Notice is dated April 10, 2026 and we plan to mail the Notice on or about April 10, 2026. The Notice contains instructions on how to access our proxy materials over the Internet. The Notice also contains instructions on how each of our shareholders can receive a paper copy of our proxy materials, including the proxy statement, our 2025 Annual Report, and a form of proxy card.

Shareholders of record at the close of business on March 23, 2026, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. A complete list of registered shareholders will be available to shareholders of record during the Annual Meeting.

Your vote is very important, regardless of the number of shares you own. Whether or not you expect to attend the Annual Meeting, please vote your shares by proxy in advance of the Annual Meeting to ensure your representation and the presence of a quorum at the Annual Meeting. To ensure that your vote is recorded promptly, please vote as soon as possible, even if you plan to attend the Annual Meeting.

If you are a shareholder of record, you may vote your shares by proxy in advance of the Annual Meeting on the Internet by visiting www.proxyvote.com, by telephone by calling 1-800-690-6903 and following the recorded instructions or by completing, signing, dating, and returning a proxy card. If you mail your proxy card or vote by telephone or the Internet and then decide to vote your shares online during the Annual Meeting, you may still do so provided you register in advance at http://www.virtualshareholdermeeting.com/PMN2026. Your proxy is revocable in accordance with the procedures set forth in the proxy statement.

If you are a non-registered shareholder, you will receive instructions from the holder of record that you must follow in order to vote your shares by proxy in advance of the Annual Meeting.

Thank you for your ongoing support and continued interest in ProMIS Neurosciences Inc.

The content and sending of the proxy statement has been authorized by order of the Board of Directors,

Neil K. Warma
Chief Executive Officer
Toronto, Ontario
April 10, 2026

Table of Contents

TABLE OF CONTENTS


PROXY STATEMENT		1
QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING		3
OWNERSHIP OF OUR COMMON SHARES		10
PROPOSAL 1 ELECTION OF DIRECTORS		14
DIRECTOR BIOGRAPHIES		13
DIRECTOR COMPENSATION		18
CORPORATE GOVERNANCE		20
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS		30
EXECUTIVE COMPENSATION		33
AUDIT COMMITTEE REPORT		39
PROPOSAL 2 RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM		43
PROPOSAL 3 ORDINARY RESOLUTION TO AMEND THE PROMIS NEUROSCIENCES INC. 2025 STOCK OPTION AND INCENTIVE PLAN		45
OTHER INFORMATION		48

Table of Contents

SUITE 200, 1920 YONGE STREET

TORONTO, ONTARIO, CANADA M4S 3E2

(416) 847-6898

PROXY STATEMENT

2026 ANNUAL MEETING OF SHAREHOLDERS

To Be Held on May 20, 2026

This proxy statement contains information about the 2026 Annual Meeting of Shareholders of ProMIS Neurosciences Inc. (the “Annual Meeting”), to be held on Wednesday, May 20, 2026 at 10:30 a.m., Eastern Time. This year’s Annual Meeting will be a virtual meeting, which will be conducted via live webcast. In order to attend the Annual Meeting, you must register at http://www.virtualshareholdermeeting.com/PMN2026. Upon completing your registration, you will receive further instructions via email, including a unique link that will allow you access to the Annual Meeting and to vote and submit questions during the Annual Meeting. There will not be a physical meeting location, and shareholders will not be able to attend the Annual Meeting in person. Further information about how to attend the Annual Meeting online is included in this proxy statement below. Except where the context otherwise requires, references to “ProMIS Neurosciences,” “ProMIS,” “company,” “we,” “us,” “our” and similar terms refer to ProMIS Neurosciences Inc. and its consolidated subsidiaries.

This proxy statement summarizes information about the proposals to be considered at the meeting and other information you may find useful in determining how to vote. We are making this proxy statement, the related proxy card and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”), available to shareholders for the first time on or about April 10, 2026.

Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”) and the Canadian Securities Administrators (the “CSA”), we are providing access to our proxy materials over the Internet instead of printing and mailing our proxy materials. As a result, we are mailing to our shareholders a Notice of Internet Availability of Proxy Materials (the “Notice”), instead of a paper copy of this proxy statement and the 2025 Annual Report. We plan to send the Notice on or about April 10, 2026. The Notice contains instructions on how each of our shareholders may access and review the proxy materials, including the Notice of Annual Meeting, proxy statement, proxy card and 2025 Annual Report, on the website referred to in the Notice. The Notice also contains instructions on how each of our shareholders may request that a paper copy of our proxy materials, including this proxy statement, our 2025 Annual Report, and a form of proxy card, be sent to such shareholder by mail.

Table of Contents

Important Notice Regarding the Availability of Proxy Materials for
the Annual Meeting of Shareholders to be Held on May 20, 2026:

This proxy statement and our 2025 Annual Report are
available for viewing, printing, and downloading at www.proxyvote.com.

A copy of our 2025 Annual Report, as filed with the Securities and Exchange Commission and with Canadian Securities Administrators, except for exhibits, will be furnished without charge to any shareholder upon written request to ProMIS Neurosciences Inc., Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada M4S 3E2, Attention: Investor Relations. Exhibits will be provided upon written request and payment of an appropriate processing fee. This proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 are also available on the SEC’s website at www.sec.gov and on the System of Electronic Document Analysis and Retrieval+ (“SEDAR+”) at www.sedarplus.ca.

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING

Q.	Why did I receive these proxy materials?

Our board of directors (the “board” or “board of directors”) has made these proxy materials available to you on the Internet in connection with our board of directors’ solicitation of proxies for use at our Annual Meeting, which will be held virtually on Wednesday, May 20, 2026 at 10:30 a.m., Eastern Time. As a holder of record of Common Shares as of the close of business on March 23, 2026 (the “Record Date”), you are invited to attend the Annual Meeting virtually and are requested to vote on the items of business described in this proxy statement. This proxy statement includes information that we are required to provide to you under SEC rules, Canadian securities laws, and the Ontario Business Corporations Act (the “OBCA”) and is designed to assist you in voting your shares.

Q:	Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?

In accordance with rules adopted by the SEC and the CSA, we may furnish proxy materials, including this proxy statement and our 2025 Annual Report, to our shareholders by providing access to such documents on the Internet instead of mailing printed copies. We believe electronic delivery will expedite the receipt of materials, will help lower our costs and reduce the environmental impact of our Annual Meeting materials. The proxy materials, including this proxy statement, a proxy card and our 2025 Annual Report, are available for viewing, printing, and downloading on the Internet at www.proxyvote.com.

Q.	What is the purpose of the Annual Meeting?

A.	At the Annual Meeting, shareholders will consider and vote on the following matters:

To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

To approve an amendment to the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan; and

To transact any other business that may properly come before the Annual Meeting or any adjournment thereof.

Q:	Why is the 2026 Annual Meeting a virtual, online meeting?

The Annual Meeting will be a “virtual meeting” of stockholders. We have implemented the virtual format in order to facilitate stockholder attendance at our Annual Meeting. We have designed our virtual format to enhance, rather than constrain, stockholder access, participation and communication. For example, the virtual format allows stockholders to communicate with us in advance of, and during, the Annual Meeting so they can ask questions of our board of directors or management.

Q:	How do I attend the virtual Annual Meeting?

The Annual Meeting will be a virtual meeting and you may not attend in person. In order to attend the meeting online, you must register in advance at www.virtualshareholdermeeting.com/PMN2026. You or your proxyholder may attend the Annual Meeting online by following the instructions you or your proxyholder receive once registration is complete. The meeting will start at 10:30 a.m., Eastern Time, on May 20, 2026.

Online registration will begin at 10:15 a.m., Eastern Time on May 20, 2026, and you should allow ample time for the online registration.

Table of Contents

Upon completing your registration, you or your proxyholder will receive further instructions via email, including a unique link that will allow access to the meeting and enable you or your proxyholder to have the ability to submit questions. Please be sure to follow instructions found on your proxy card and/or voting authorization form and subsequent instructions that will be delivered to you via email.

You or your proxyholder may log on to the virtual meeting starting one hour before it begins. If you or your proxyholder encounter any difficulties accessing the virtual meeting during check-in or at the time of the virtual meeting, please contact technical support, whose contact information will be included in the email containing the unique link granting access into the meeting. There will be technicians standing by and ready to assist you with any technical difficulties you may have accessing the virtual meeting starting at 10:15 a.m., Eastern Time, on May 20, 2026.

Please note that you or your proxyholder can only access the virtual Annual Meeting via your unique link to the Annual Meeting that will be emailed to you or your proxyholder if registration was properly submitted.

Q.	How do I submit a question at the Annual Meeting?

If you or your proxyholder wish to submit a question during the Annual Meeting, you or your proxyholder must log into the virtual meeting platform using the unique link provided to you or your proxyholder via email following the completion of your registration at www.virtualshareholdermeeting.com/PMN2026, type your question into the “Ask a Question” field, and click “Submit.” Our virtual meeting will be governed by our Rules of Conduct which will be posted in advance of the meeting. The Rules of Conduct will address the ability of shareholders to ask questions during the meeting, including rules on permissible topics, and rules for how questions and comments will be recognized and disclosed to meeting participants.

Q:	Who can vote at the Annual Meeting?

To be entitled to vote, you must have been a shareholder of record at the close of business on March 23, 2026, the record date for our Annual Meeting. A total of 8,967,693 of our common shares, no par value (“Common Shares”) were outstanding and entitled to vote at the Annual Meeting as of the record date. Only shareholders of record at the close of business on the Record Date who either (i) attend the Annual Meeting personally following the instructions above (see How do I attend the virtual Annual Meeting above) or, (ii) complete, sign and deliver the proxy card in the manner and subject to the provisions described below, or (iii) vote in one of the manners provided for in the voting instruction form (the “VIF”), will be entitled to vote or to have their Common Shares voted at the Annual Meeting, except to the extent that:

(a) the shareholder has transferred the ownership of any such share after the Record Date, and

(b) the transferee produces a properly endorsed share certificate for or otherwise establishes ownership of any of the transferred Common Shares and makes a demand to Computershare no later than 10 days before the Meeting that the transferee’s name be included in the list of shareholders in respect thereof.

Q.	How many votes do I have?

A.	Each Common Share that you own as of the record date will entitle you to one vote on each matter considered at the Annual Meeting.

Q.	How do I vote?

A.	If you are the “record holder” of your shares, meaning that your shares are registered in your name in the records of our transfer agent, Computershare Trust Company of Canada and Computershare Trust Company, N.A., you may vote your shares at the meeting in person or by proxy as follows:

(1)

Via the Internet prior to the Annual Meeting: To vote over the Internet prior to the Annual Meeting, please go to the following website: www.proxyvote.com, and follow the instructions at that site for submitting your

Table of Contents

proxy electronically. If you vote your proxy over the Internet prior to the Annual Meeting, you do not need to complete and mail your proxy card or vote your proxy by telephone.

(2)

By Telephone: To vote by telephone, please call 1-800-690-6903 and follow the instructions provided on the proxy card. If you vote by telephone, you do not need to complete and mail your proxy card or vote your proxy over the Internet.

(3)

By Mail: To vote by mail, you must mark, sign and date the proxy card and then mail the proxy card in accordance with the instructions on the proxy card. If you vote by mail, you do not need to vote over the Internet or by telephone. If you return your proxy card but do not specify how you want your shares voted on any particular matter, they will be voted in accordance with the recommendations of our board of directors.

(4)

Via the Internet during the Annual Meeting: In order to vote during the virtual meeting, you must register in advance at www.virtualshareholdermeeting.com/PMN2026. You may then attend the Annual Meeting virtually and vote online by logging into the virtual meeting platform using the unique link provided to you via email following the completion of your registration at www.virtualshareholdermeeting.com/PMN2026. If you vote your proxy prior to the Annual Meeting and choose to attend the Annual Meeting online, there is no need to vote again during the Annual Meeting unless you wish to change your vote.

If you are a shareholder of record and do not vote through the internet, by telephone, by completing the proxy card that may be delivered to you or online during the Annual Meeting, your shares will not be voted.

If you are a non-registered shareholder because your shares are held in “street name”, meaning they are held for your account by an intermediary, such as a broker, bank or other nominee, then your intermediary that actually holds the shares for you is the record holder and is required to vote the shares it holds on your behalf according to your instructions. You will receive the proxy materials, as well as voting and revocation instructions, from your intermediary or its agent. You may vote your shares at the meeting by proxy by following the instructions that your broker, bank, or other nominee provides you. If you wish to vote your shares virtually at the Annual Meeting, you must:

(1)

Appoint yourself as your proxyholder: U.S. non-registered shareholders—follow the instructions your intermediary has provided in the VIF sent to you about how to request that a legal proxy to appoint you as a proxyholder, or contact your intermediary right away to request a legal proxy form if you have not received a voting instruction form. Your intermediary may send to you a legal proxy that you may be required to submit prior to the Annual Meeting, but do follow the instructions you receive. Canadian non-registered shareholders—print your name in the blank space provided for appointing a proxyholder on the VIF and follow the instructions provided by your intermediary for mailing your voting instructions. Your intermediary may allow you to do this online or by telephone instead. Do not complete the voting section because you will vote in real time at the meeting. You need to act promptly to allow enough time for your intermediary to receive your instructions and to forward them so that you can register to vote at the Annual Meeting.

(2)

Register your proxyholder: After you have appointed yourself as proxyholder, you must register in advance at www.virtualshareholdermeeting.com/PMN2026.

(3)

Log In to the virtual Annual Meeting: Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you to access the meeting and will permit you to submit questions. You may attend the Annual Meeting virtually and vote online by logging into the virtual meeting platform using the unique link provided to you via email.

If you do not give instructions to your broker, bank or other nominee, and your intermediary does not have discretionary authority to vote the non-registered shareholder’s shares on the matter, or elects not to vote in the absence of instructions from the non-registered shareholder, no votes will be cast on your behalf with respect to such item (a “broker non-vote”). If you are a non-registered shareholder whose Common Shares are held of record by a broker, New York Stock Exchange rules, which are also applicable to Nasdaq-listed companies, permit your broker to exercise

Table of Contents

discretionary voting authority with respect to certain “discretionary” items. The ratification of the appointment of Baker Tilly US, LLP as our independent registered public accounting firm (Proposal 2) is considered a discretionary item under such rules. All of the other matters being put to a vote are “non-discretionary” items. Accordingly, under New York Stock Exchange rules your broker may not vote your shares with respect to these other matters.

If you have not completed the steps outlined above, you may still attend the meeting as a guest. However, you will not be able to vote your shares at the meeting.

Q.	How do I appoint a proxyholder?

A.	Your proxyholder is the person you appoint to cast your votes on your behalf. You can choose anyone you want to be your proxyholder; it does not have to be either of the persons we have designated in the proxy card, nor does it have to be a shareholder.

The persons named as proxyholder in the proxy card will vote or withhold from voting the Common Shares represented thereby in accordance with your instructions on any ballot that may be called for. If you specify a choice with respect to any matter to be acted upon, your Common Shares will be voted accordingly. The proxy card confers discretionary authority on persons named as proxyholder therein with respect to: (a) each matter or group of matters identified therein for which a choice is not specified, other than the appointment of an auditor and the election of directors, (b) any amendment to or variation of any matter identified therein, and (c) any other matter that properly comes before the Meeting. In respect of a matter for which a choice is not specified in the completed Proxy, the persons named as proxyholder in the Proxy will vote the Common Shares represented by the Proxy for the approval of such matter. Since the Annual Meeting will take place virtually, the process for appointing another person as your proxyholder (other than the board nominated proxies named in the proxy card) to access the Annual Meeting and vote on your behalf is different than it would be for an in-person meeting. If you would like your proxyholder to attend and vote at the virtual Annual Meeting on your behalf, you must:

(1)

Appoint your proxyholder: U.S. non-registered shareholders—follow the instructions your intermediary has provided in the VIF sent to you about how to request that a legal proxy to appoint someone else as a proxyholder, or contact your intermediary right away to request a legal proxy form if you have not received a VIF. Your intermediary may send to you a legal proxy that you may be required to submit prior to the Annual Meeting, but do follow the instructions you receive. Canadian non-registered shareholders—print the name of your proxyholder in the blank space provided for appointing a proxyholder on the VIF and follow the instructions provided by your intermediary for mailing your voting instructions. Your intermediary may allow you to do this online or by telephone instead. Do not complete the voting section because you will vote in real time at the meeting. You need to act promptly to allow enough time for your intermediary to receive your instructions and to forward them so that you can register your proxyholder to vote at the Annual Meeting.

(2)

Register your proxyholder: After you have appointed your proxyholder, you must register your proxyholder in advance at www.virtualshareholdermeeting.com/PMN2026.

Upon completing your registration, your proxyholder will receive instructions via email, including a unique link that will allow your proxyholder to access the meeting and will permit your proxyholder to submit questions. Your proxyholder may attend the Annual Meeting virtually and vote online by logging into the virtual meeting platform using the unique link provided to them via email.

Q.	Can I change my vote?

A.	If your shares are registered directly in your name, you may revoke your proxy and change your vote at any time before the vote is taken at the Annual Meeting. To do so, you must do one of the following:

(1)

Vote over the Internet or by telephone as instructed above. Only your latest Internet or telephone vote is counted.

Table of Contents

(2)

Sign and return a new proxy card. Only your latest dated proxy card will be counted.

(3)

Attend the Annual Meeting virtually and vote online as instructed above. Attending the Annual Meeting virtually will not, by itself, revoke your Internet vote, telephone vote or proxy card submitted by mail, as the case may be. Your prior vote will be revoked only to the extent you vote on-line at the Annual Meeting.

(4)

Notify our corporate secretary in writing before the Annual Meeting that you want to revoke your proxy.

If your shares are held in “street name” and you are a non-registered shareholder, you may submit new voting instructions with a later date by contacting your broker, bank, or other nominee. You must provide any new voting instructions prior to the deadline specified by your intermediary to ensure your shares are voted in the way you prefer.

Q.	How many shares must be represented to have a quorum and hold the Annual Meeting?

A quorum for a meeting of shareholders shall be two shareholders, or two proxyholders representing shareholders, or combination thereof, holding not less than thirty-three and one third percent (33^1/3%) of the issued shares entitled to be voted at in the meeting. If there is only one shareholder the quorum is one person present and being, or representing by proxy, such shareholder. For purposes of determining whether a quorum exists, we count as present any shares that are voted over the Internet, by telephone or by submitting a proxy card or that are represented in person at the meeting. Further, for purposes of establishing a quorum, we will count as present shares that a shareholder holds even if the shareholder votes to abstain or only votes on one of the proposals. If a quorum is not present, we expect to adjourn the Annual Meeting until we obtain a quorum. There were 8,967,693 Common Shares outstanding and entitled to vote on the record date. Therefore, a quorum will be present if 2,989,231 Common Shares are present in person or represented by executed proxies timely received by us at the Annual Meeting. Common Shares present virtually during the Annual Meeting will be considered Common Shares represented in person at the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement.

Q.	What is a “broker non-vote” and which proposals are considered “routine” or “non-routine”?

At most public companies, the vast majority of shareholders hold their shares through brokerage firms, banks, or other intermediaries rather than directly as shareholders of record. These shareholders are frequently referred to as “beneficial owners.” Unlike shareholders of record, beneficial owners are not entitled to vote directly at a shareholder meeting. Instead, they must instruct their broker, bank, or other nominee how to vote the shares held on their behalf. If a beneficial owner submits voting instructions, the broker or other nominee will vote those shares in accordance with those instructions.

If a beneficial owner does not submit voting instructions, the result may be a “broker non-vote.” Under the rules of the New York Stock Exchange, which are also applicable to Nasdaq-listed companies such as ProMIS, brokers, banks, and other securities intermediaries that are subject to New York Stock Exchange rules may use their discretion to vote “uninstructed” shares on matters considered to be “routine” under New York Stock Exchange rules, but not with respect to “non-routine” matters. A broker non-vote occurs when a broker, bank, or other agent has not received voting instructions from the beneficial owner and cannot vote the shares because the matter is considered "non-routine" under NYSE rules.

The proposals to be voted on at the Annual Meeting have been assessed as follows:

●

Proposal 1 — Election of “Directors is considered a non-routine matter under New York Stock Exchange rules. Accordingly, if your shares are held in “street name” and you do not instruct your broker, bank, or other nominee how to vote your shares, your broker, bank, or other nominee may not vote your shares on Proposal 1 in the absence of your voting instructions. Broker non-votes are not considered votes cast and will have no effect on the outcome of the election of directors.

●

Proposal 2 — Ratification of the Appointment of Baker Tilly US, LLP is considered a routine matter under New York Stock Exchange rules. Accordingly, if your shares are held in "street name" and you do not instruct

Table of Contents

your broker, bank, or other nominee how to vote your shares, your broker, bank, or other nominee may vote your shares on Proposal 2 in its discretion. Because Proposal 2 is a routine matter, broker non-votes are not expected on this proposal.

●

Proposal 3 — Approval of the Amendment to the 2025 Plan is considered a non-routine matter under New York Stock Exchange rules. Accordingly, if your shares are held in “street name” and you do not instruct your broker, bank, or other nominee how to vote your shares, your broker, bank, or other nominee may not vote your shares on Proposal 3 in the absence of your voting instructions. Broker non-votes will have no effect on the outcome of the vote on Proposal 3.

We encourage all shareholders — and in particular those who hold their Common Shares through a broker, bank, or other nominee — to submit their voting instructions promptly to ensure that their shares are voted on all proposals.

Q.	What vote is required to approve each matter and how are votes counted?

Proposal 1—Election of Directors. You may vote for nominee directors or withhold your vote. Votes that are WITHHELD will not count as votes cast and will have no effect on the election of director nominees. Broker non-votes are not considered votes cast and will likewise have no effect on the outcome of the election. If your shares are held by your broker, bank, or other nominee in “street name” and you do not vote your shares, your broker may not vote your unvoted shares on Proposal 1. You may:

●

vote FOR all nominees;

●

WITHHOLD your vote for all nominees; or

●

vote FOR or WITHHOLD your vote for one or more nominees.

Proposal 2 — Ratification of the Appointment of Our Independent Registered Public Accounting Firm. The affirmative vote of the holders of Common Shares representing a majority of the votes cast on the matter is required to ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. Abstentions and broker non-votes, if any, will have no effect on the voting on the proposal referenced above.

Proposal 3— Approval of the amendment to the 2025 Plan to increase the number of shares of our Common Shares available for issuance thereunder by 900,000 Common Shares. The affirmative vote of the holders of Common Shares representing a majority of the votes cast on the matter is required to pass this proposal. Abstentions and broker non-votes, if any, will have no effect on the voting on the proposal referenced above. If your shares are held by your broker, bank, or other nominee in “street name” and you do not vote your shares, your broker may not vote your unvoted shares on Proposal 3.

Q.	Who will count the vote?

A.	The votes will be counted, tabulated, and certified by Broadridge Financial Solutions.

Q.	How does the board of directors recommend that I vote on the proposals?

A.	Our board of directors recommends that you vote:

FOR the election of each director;

FOR the ratification of the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and

FOR the approval of the amendment to the 2025 Plan.

Table of Contents

If you appoint the persons we have designated in the proxy card as your proxyholder, your shares will be voted for or against from voting in accordance with your instructions on any ballot that may be called for and, if no instructions are provided will be voted as recommended by the board of directors.

Q.	Are there other matters to be voted on at the Annual Meeting?

We do not know of any matters that may come before the Annual Meeting other than the matters noted above. If any other matters are properly presented at the Annual Meeting, the persons named in the accompanying proxy card intend to vote, or otherwise act, in accordance with their judgment on the matter.

Q.	Where can I find the voting results?

We plan to announce preliminary voting results at the Annual Meeting and will report final voting results in a Current Report on Form 8-K (“Form 8-K”), that we expect to file with the SEC within four business days, and promptly with Canadian securities regulators, following the conclusion of our Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results, and within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.

Q.	How are proxies solicited for the Annual Meeting and what are the costs of soliciting these proxies?

Our board of directors is soliciting proxies for use at the Annual Meeting by means of the proxy materials. We will bear the cost of proxy solicitation by the board of directors. In addition to solicitation by mail, our directors, officers, and employees may solicit proxies by telephone, e-mail, facsimile and in person without additional compensation being paid by us. We are not sending proxy-related materials directly to non-objecting, non-registered shareholders, and such materials will be delivered to non-objecting, non-registered shareholders by the non-objecting, non-registered shareholders’ intermediary. We may engage a solicitor to assist in the solicitation of proxies for a fee in the range of approximately $10,000 to $15,000 plus customary costs and expenses for these services.

Q.	I share an address with another shareholder, and we received only one paper copy of proxy materials. How may I obtain an additional copy of the proxy materials?

Intermediaries are permitted to adopt a procedure called “householding,” which has been approved by the SEC. Under this procedure, your intermediary may deliver a single notice and, if applicable, the proxy materials, will be delivered to multiple shareholders sharing an address unless contrary instructions have been received. Once you have received notice from your intermediary that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If you prefer to receive multiple copies of the proxy materials at the same address you can request additional copies by contacting your broker or contacting us at our principal executive offices, ProMIS Neurosciences Inc., Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada M4S 3E2, Attn: Investor Relations, telephone: (416) 847-6898.

Table of Contents

OWNERSHIP OF OUR COMMON SHARES

The board has fixed March 23, 2026 as the record date for determination of persons entitled to receive notice of the Meeting (the “Record Date”). Only shareholders of record at the close of business on the Record Date who either (i) attend the Annual Meeting personally following the instructions above (see How do I attend the virtual Annual Meeting above) or, (ii) complete, sign and deliver the proxy card in the manner and subject to the provisions described above, or (iii) vote in one of the manners provided for in the VIF, will be entitled to vote or to have their Common Shares voted at the Annual Meeting, except to the extent that:

(a) the shareholder has transferred the ownership of any such share after the Record Date, and

The Company is authorized to issue an unlimited number of Common Shares and an unlimited number of preferred shares, each class having rights, privileges, restrictions and conditions attached to them as set out in the Articles of Amalgamation of the Company. The Common Shares are listed for trading on Nasdaq under the stock symbol “PMN”. As of March 23, 2026, the Company had outstanding 8,967,693 fully paid and non-assessable Common Shares , each carrying the right to one vote.

Holders of Common Shares are entitled to one vote per Common Share at meetings of shareholders. No group of Shareholders has the right to elect a specified number of directors, nor are there cumulative or similar voting rights attached to the Common Shares.

Unless otherwise provided below, the following table sets forth information regarding beneficial ownership of our Common Shares as of March 23, 2026 by:

●

each person, or group of affiliated persons, known to us to be the beneficial owner of 5% or more of our Common Shares outstanding;

●

each of our current directors;

●

our principal executive officer and our other executive officers who served during the year ended December 31, 2025, named in the Summary Compensation table below, whom, collectively, we refer to as our named executive officers; and

●

all of our directors and executive officers as a group.

Beneficial ownership is determined in accordance with SEC rules. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include Common Shares issuable upon the exercise of stock options that are immediately exercisable or exercisable within 60 days after March 23, 2026. Except as otherwise indicated, all of the shares reflected in the table are Common Shares and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose.

Table of Contents

The column entitled “Percentage of Shares Beneficially Owned” is based on a total of 8,967,693 Common Shares outstanding as of March 23, 2026. Except as otherwise indicated in the footnotes below, the address of the beneficial owner is c/o ProMIS Neurosciences Inc., Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada M4S 3E2.


		Amount and Nature of Beneficial		Percent of
Name and Position of Beneficial Owner		Ownership		Class
Directors and Executive Officers
Neil Warma, Chief Executive Officer		54,617	⁽¹⁾	*	%
Neil Cashman, Chief Scientific Officer & Director		19,059	⁽²⁾	*	%
Johanne Kaplan, Chief Development Officer		11,797	⁽³⁾	*	%
Eugene Williams, Chairman of the Board		16,443	⁽⁴⁾	*	%
Madge “Maggie” K. Shafmaster, Lead Independent Director		9,713	⁽⁵⁾	*	%
William Wyman, Director		4,689	⁽⁶⁾	*	%
Patrick Kirwin, Director		12,462	⁽⁷⁾	*	%
Josh Mandel-Brehm, Director		1,713	⁽⁸⁾	*	%
Slanix Alex, Director		499	⁽⁹⁾	*	%
All directors and executive officers as a group (11 people)		135,794	⁽¹⁰⁾	1.50	%
>5% Shareholders
Entities affiliated with Janus Henderson		1,354,393	⁽¹¹⁾	14.99	%
Entities affiliated with Ally Bridge Group		943,089	⁽¹²⁾	9.99	%
Entities affiliated with Deep Track		903,552	⁽¹³⁾	9.99	%
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.		919,010	⁽¹⁴⁾	9.99	%
Trails Edge Biotechnology Master Fund, LP		934,468	⁽¹⁵⁾	9.99	%
Entities Affiliated with Great Point		955,078	⁽¹⁶⁾	9.99	%
Entities Affiliated with Sphera		802,489	⁽¹⁷⁾	8.60	%
Entities Affiliated with Jeremy Sclar		768,494	⁽¹⁸⁾	8.30	%
Woodline Master Fund LP		742,804	⁽¹⁹⁾	7.95	%
Shaf QIC, LLC		681,364	⁽²⁰⁾	7.30	%
Squadron Master Fund LP		649,954	⁽²¹⁾	7.00	%

*	Represents beneficial ownership of less than 1% of our outstanding Common Shares.

(1)	Includes 6,183 Common Shares, 42,251 Common Shares underlying options exercisable within 60 days of March 23, 2026, and 6,183 Common Shares underlying warrants exercisable within 60 days of March 23, 2026.

(2)

Includes 9,318 Common Shares, of which 665 Common Shares are held by Rosemary Cashman, Dr. Cashman’s spouse, 5,152 Common Shares underlying options exercisable within 60 days of March 23, 2026, 4,547 Common Shares underlying warrants exercisable within 60 days of March 23, 2026, and 42 Common Shares underlying deferred stock units (“DSUs”).

(3)	Includes 3,941 Common Shares, 5,796 Common Shares underlying options exercisable within 60 days of March 23, 2026, and 2,060 Common Shares underlying warrants exercisable within 60 days of March 23, 2026.

(4)	Includes 12,397 Common Shares and 4,046 Common Shares underlying options exercisable within 60 days of March 23, 2026.

(5)	Represents 8,000 Common Shares and 1,713 Common Shares underlying options exercisable within 60 days of March 23, 2026.

(6)	Includes 2,517 Common Shares and 1,879 Common Shares underlying options exercisable within 60 days of March 23, 2026.

(7)

Includes 5,135 Common Shares held directly, 1,653 Common Shares held by Patrick D. Kirwin Professional Corporation, and 306 Common Shares held by Mr. Kirwin’s spouse. Also includes 1,879 Common Shares underlying options exercisable within 60 days of March 23, 2026 and 3,490 Common Shares underlying warrants exercisable within 60 days of March 23, 2026. Mr. Kirwin will depart our board of directors effective at the Annual Meeting.

(8)	Represents Common Shares underlying options exercisable within 60 days of March 23, 2026.

(9)

Represents Common Shares underlying options exercisable within 60 days of March 23, 2026. The options are held by and for the benefit of Ally Bridge MedAlpha Master Fund, LP. Dr. Alex is the Portfolio Manager of the fund and disclaims any beneficial ownership of these shares except to the extent of his pecuniary interest in the fund.

Table of Contents

(11)

Includes all current company Executive Officers and Directors, which includes Daniel Geffken and Dr. Larry Altstiel. Includes 49,683 Common Shares, 69,290 Common Shares underlying options exercisable within 60 days of March 23, 2026, 16,280 shares underlying warrants exercisable within 60 days of March 23, 2026, and 42 shares underlying DSUs.

(12)

Consists of (i) 1,292,757 Common Shares, (ii) 100,000 Common Shares underlying Pre-funded Warrants, and (iii) 1,392,757 Common Shares underlying Warrants. The exercisability of the Pre-funded and Common Share Warrants is subject to a 14.99% ownership limitation blocker. The securities held by Janus Henderson Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation Master Fund II Limited may be deemed to be beneficially owned by Janus Henderson Investors US LLC (“Janus”), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for the Fund and has the ability to make decisions with respect to the voting and disposition of the shares subject to the oversight of the board of directors of the Fund. Under the terms of its management contract with the Fund, Janus has overall responsibility for directing the investments of the Fund in accordance with the Fund’s investment objective, policies and limitations. The Fund has one or more portfolio managers appointed by and serving at the pleasure of Janus whom makes decisions with respect to the disposition of the Common Shares offered hereby. The portfolio managers for this Fund are: Andrew Acker, Daniel S. Lyons and Agustin Mohedas. The address of Janus is 151 Detroit Street, Denver, CO 80206.

(13)

Consists of (i) 943,089 Common Shares, (ii) 50,990 Common Shares underlying pre-funded warrants, 1,037,351 Common Shares underlying Warrants, and (iv) 499 Common Shares underlying Options exercisable within 60 days of March 23, 2026. The exercisability of the Pre-funded and Common Share Warrants is subject to a 9.99% ownership limitation blocker. Mr. Fan Yu is the sole stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. ABG V-SIV IX Limited is 100% owned by Ally Bridge Group Global Life Science Capital Partners V, L.P. (“ABG Fund V”). Mr. Fan Yu is the director of the entity that acts as the ultimate general partner of ABG Fund V, and has the ultimate decision-making and voting power in respect of the shares owned by ABG V-SIV IX Limited.Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages investments of Ally Bridge MedAlpha Master Fund L.P. (“MedAlpha”). As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held by MedAlpha. Dr. Slanix Alex serves as President and Portfolio Manager of MedAlpha and as a Director on the Board of Directors of the Company. Notwithstanding the above, each of them disclaims any such beneficial ownership in the shares of MedAlpha, except to the extent of their respective pecuniary interest. The address of MedAlpha is c/o Ally Bridge Group (NY) LLC, 430 Park Avenue, 12th Floor, New York, NY 10022.

(14)

Consists of (i) 835,655 Common Shares and (ii) 835,655 Common Shares underlying Warrants. The exercisability of the Common Share Warrants is subject to a 9.99% ownership limitation blocker. Mr. David Kroin is the Managing Member of Deep Track Capital GP, LLC the investment manager of Deep Track Capital, LP. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital LP and Mr. David Kroin may be deemed to be considered beneficial owners of the securities held by Deep Track Biotechnology Master Fund, Ltd. The business address of foregoing entities and individuals is 200 Greenwich Avenue, 3rd Floor, Greenwich, CT 06830.

(15)

Consists of (i) 696,378 Common Shares and (ii) 696,378 Common Shares underlying Warrants. The exercisability of the Common Share Warrants is subject to a 9.99% ownership limitation blocker. Wellington Management Company LLP (“WMC”) has the power to vote and dispose the securities pursuant to WMC’s investment management relationship with the Stockholder. WMC is a subsidiary of Wellington Management Group LLP (“WMG”). WMG is a Massachusetts limited liability partnership, privately held by 181 partners (as of July 1, 2025). There are no external entities with any ownership interest in the firm. Individual percentages of ownership are confidential. However, no single partner owns or has the right to vote more than 5% of the Partnership’s capital. Additional information about WMC is available in Form ADV filed with the SEC. The address of WMC is c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210.

(16)

Consists of (i) 557,103 Common Shares and (ii) 557,103 Common Shares underlying Warrants. The exercisability of the Common Share Warrants is subject to a 9.99% ownership limitation blocker. The securities are held by Trails Edge Biotechnology Master Fund, LP (“Trails Edge Biotechnology”). Trails Edge Capital Partners, LP (“Trails Edge Capital”), as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own such securities. The address of these funds and persons is 3455 Peachtree Road NE, Atlanta, GA 30326.

(17)

Consists of (i) 371,402 Common Shares, (ii) 18,691 Common Shares underlying pre-funded warrants, and (iii) 632,040 Common Shares underlying warrants. The exercisability of the Common Share Warrants is subject to a 9.99% ownership limitation blocker. Great Point Partners, LLC (“Great Point”) is the investment manager of Biomedical Value Fund, L.P. (“BVF”) and Biomedical Offshore Value Fund, Ltd. (“BOVF”), and by virtue of such status may be deemed to be the beneficial owner of the BVF and BOVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl (“Ms. Nordahl”), as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BVF and BOVF Shares. Notwithstanding the above, Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to

Table of Contents

the extent of their respective pecuniary interests. The address of Great Point is 165 Mason Street, 3rd Floor, Greenwich, CT 06830.

(18)

Consists of (i) 336,784 Common Shares and (ii) 465,705 Common Shares underlying Warrants. Sphera Global Healthcare Management LP has voting and dispositive power over the securities held by Sphera Global Healthcare Master Fund and Sphera Biotech Master Fund, L.P. The address of Sphera Global Healthcare Management LP is 4 Yitzhak Sade, Building A, 29th Floor, Tel Aviv 6777520, Israel.

(19)

Consists of (i) 383,144 Common Shares and (ii) 385,350 Common Shares underlying Warrants. Jeremy M. Sclar has voting and dispositive power over the securities held by the Jeremy M. Sclar 2012 Irrevocable Family Trust. The address of Jeremy Sclar is 33 Boylston Street, Suite 3000, Chestnut Hill, MA 02467

(20)

Consists of (i) 371,042 Common Shares and (ii) 371,042 Common Shares underlying Warrants. These securities are held by Woodline Master Fund LP. Woodline Partners LP serves as the investment manager of Woodline Master Fund LP and may be deemed to be the beneficial owner of the shares. Woodline Partners LP disclaims any beneficial ownership of these shares. The address of the Fund is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.

(21)	Consists of (i) 337,380 Common Shares and (ii) 343,984 Common Shares underlying Warrants. Mr. Jonathan Shafmaster has voting and dispositive power over the securities held by SHAF QIC LLC. The address of SHAF QIC LLC is 158 Shattuck Way Newington NH 03801.

(22)

Consists of (i) 324,977 Common Shares and (ii) 324,977 Common Shares underlying Warrants. These securities are held by Squadron Master Fund LP. Squadron Capital Management LLC serves as investment adviser to Squadron Master Fund LP and may be deemed to be the beneficial owner of all securities held by the fund. Matthew Sesterhenn and William F. Blank III, as Partners of Squadron Capital Management LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all securities held by the funds. Squadron Capital Management LLC and Messrs. Sesterhenn and Blank disclaim beneficial ownership over any of the securities. The address of Squadron Capital Management LLC is 999 Oakmont Plaza Drive, Suite 600, Westmont, IL 60559.

Table of Contents

PROPOSAL 1

ELECTION OF DIRECTORS

Our board of directors is elected each year at the annual meeting of shareholders. Each director elected to hold office will do so until the 2027 annual meeting of shareholders (the “2027 Annual Meeting”) and until his or her successor is elected and qualified, or until such director’s earlier death, resignation, or removal.

The board of directors, upon the recommendation of the corporate governance and nominating committee, has nominated Neil Cashman, Eugene Williams, Maggie Shafmaster, William Wyman, Josh Mandel-Brehm, Neil Warma, and Slanix Alex for election as a director. Each person nominated for election to our board of directors is currently serving as a director of ProMIS. The board of directors has determined that Patrick Kirwin will not stand for re-election at the upcoming Annual Meeting. The board of directors thanks Mr. Kirwin for his service and contributions to the Company. The board of directors is pleased to nominate Slanix Alex as a new independent director candidate. He brings strong expertise in the areas of capital formation and M&A and the board of directors believes this nomination reflects its ongoing commitment to strong, forward-looking governance. The board of directors recommends a vote FOR the election of Slanix Alex.

Each nominee has agreed to serve if elected, and we do not know any reason why any nominee would be unable to serve. In the event that any nominee should be unavailable for election, proxies will be voted for the election of a substitute nominee designated by the board of directors or for election of only the remaining nominees.

Unless authority to do so is withheld, shares represented by executed proxies will be voted for the election of the seven nominees named below. Proxies cannot be voted for a greater number of persons than the number of nominees standing for election.

Following the board of director’s decision not to nominate Mr. Kirwin for re-election at the upcoming Annual Meeting, Mr. Kirwin submitted a statement pursuant to Section 123 of the Ontario Business Corporations Act, which is included as Appendix C to this proxy statement.

The board of directors wishes to provide shareholders with the following context.

In mid-2025, the board of directors, through its corporate governance and nominating committee, commenced a structured review of board composition as part of its ongoing commitment to maintaining an effective and well-functioning board of directors whose collective qualifications remain aligned with the Company’s strategic priorities, including the advancement of the ongoing clinical trial for PMN310. As part of this process, Dr. Slanix Alex was appointed to the board of directors as an independent director in October 2025. Dr. Alex is President and Portfolio Manager for the Public Equity strategy at Ally Bridge Group (“ABG”), holds a PharmD designation, is a licensed pharmacist, a significant shareholder in the Company through his fund, ABG, and brings extensive experience in capital markets and business development within the biotechnology sector.

In conducting its review, the corporate governance and nominating committee considered, among other factors: (i) the size and overall composition of the board of directors, including the proportion of independent directors; (ii) the functioning and effectiveness of the board of directors as a whole; and (iii) the individual qualifications, performance, and tenure of each director. Based on this review, the corporate governance and nominating committee recommended, and the board of directors determined, not to nominate Mr. Kirwin for re-election at the upcoming Annual Meeting. Prior to the board of directors’ determination, the chairman of the board of directors, the chair of the corporate governance and nominating committee and the Chief Executive Officer each spoke with Mr. Kirwin personally, expressed the board of directors’ gratitude for his many years of service and explained the rationale for the board of directors’ decision. The board of directors thanks Mr. Kirwin for his many years of service and his contributions to the Company.

Table of Contents

For the avoidance of doubt, Mr. Kirwin has not been removed from the board of directors. He continues to serve as a director and the board of directors expects that he will do so until the conclusion of the Annual Meeting, at which point his term of office will expire in the ordinary course.

The board of directors remains committed to the ongoing evolution of its composition to ensure that the collective qualifications, experience, and perspectives of its members continue to meet the changing needs of the Company as it advances through this important stage of its clinical and commercial development.

With respect to Mr. Kirwin's comments regarding business development matters, the board of directors notes that the Company is well-positioned to evaluate and pursue opportunities that are in the best interests of the Company and its shareholders. The board of directors and senior management team collectively bring deep expertise in clinical development, capital markets, pharmaceutical sciences, and biotechnology business development. The board of directors is satisfied that all business development matters are subject to rigorous oversight through its established governance processes, and that the independent members of the board of directors and its committees have both the qualifications and the mandate to assess all such opportunities with appropriate diligence.

The board of directors believes the foregoing process was thorough, principled, and conducted in the best interests of the Company and its shareholders.

Vote Required

Directors are elected by a plurality of the votes cast. This means that the eight director nominees receiving the highest number of FOR votes will be elected as directors. Votes that are WITHHELD will not count as votes cast and will have no effect on the election of director nominees. Broker non-votes are not considered votes cast and will likewise have no effect on the outcome of the election. OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE SHAREHOLDERS VOTE “FOR” THE ELECTION OF EACH DIRECTOR NOMINEE TO SERVE UNTIL THE 2027 ANNUAL MEETING.

Table of Contents

DIRECTOR BIOGRAPHIES

Below are the names, ages and certain other information for the nominees for election to our board of directors. Information with respect to the number of Common Shares beneficially owned by each director as of March 23, 2026 appears above under the heading “Ownership of Our Common Shares.” In addition to the detailed information presented below for each of our directors, we also believe that each of our directors is qualified to serve on our board of directors and has the integrity, business acumen, knowledge and industry experience, diligence, freedom from conflicts of interest and the ability to act in the interests of our shareholders.



Name		Principal Occupation, Business or Employment	Period as a Director of the Company	Common Shares Beneficially Owned or Controlled

Neil Warma Chief Executive Officer and Director, California, USA Age: 63		Chief Executive Officer of the Company since January 2024, Former President and CEO of Genexine, Inc. from April 2022 to November 2023, Former General Manager of I-Mab Biopharma, since September 2019; Founder and CEO BioHealth Care, since 2018; Executive Chairman of Ridgeline Therapeutics, since 2019; Director of TGM Biosciences since 2018.	Since May 20, 2021	54,617⁽¹⁾
Neil Cashman Director, CSO, British Columbia, Canada Age: 74		Director and Chief Scientific Officer of the Company; Professor, University of British Columbia (UBC); Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases (UBC); Director, ALS Clinic Vancouver General.	September 21, 2005 to January 9, 2008 and since June 9, 2010	19,059⁽²⁾
Eugene Williams Director, Massachusetts, USA Age: 66		Chairman and former Chief Executive Officer of the Company; CEO of Autoimmunity BioSolutions since November 2024 and SVP Strategy for Acta Pharmaceuticals since November 2022.	Since June 29, 2015	16,443⁽³⁾
Maggie Shafmaster ^{(9), (11)} Lead Independent Director, Florida, USA,		Independent consultant since 2014, providing strategic advice related to IP portfolio	Since September 22, 2021	9,713⁽⁴⁾

Table of Contents



Name		Principal Occupation, Business or Employment	Period as a Director of the Company	Common Shares Beneficially Owned or Controlled

Age: 67		development, commercial transactions and potential and ongoing patent and trade secret disputes.
William Wyman ^{(8), (9), (10), (11)} Director, New Hampshire, USA Age: 88		Director of the Company; Management consultant; Director of Allston Trading, a trading firm; Founder of Oliver Wyman, a management consulting firm.	Since March 8, 2014	4,689⁽⁵⁾
Josh Mandel-Brehm ^{(8), (10), (11)} Director, Massachusetts, USA Age: 43		President and Chief Executive Officer, CAMP4 Therapeutics Corporation, since May 2017; Entrepreneur Partner, Polaris Partners, since May 2017; Founder, Vico Therapeutics, since September 2019.	Since September 1, 2021	1,713⁽⁶⁾
Slanix Alex ⁽¹¹⁾ Director, Florida, USA Age: 36		President and Portfolio Manager for Ally Bridge Group’s Public Equity strategy since 2023	Since October 22, 2025	499⁽⁷⁾

(1)	Includes 6,183 Common Shares, 42,251 Common Shares underlying options exercisable within 60 days of March 23, 2026, and 6,183 Common Shares underlying warrants exercisable within 60 days of March 23, 2026.

(2)

(3)	Includes 12,397 Common Shares and 4,046 Common Shares underlying options exercisable within 60 days of March 23, 2026.

(4)	Includes 8,000 Common Shares and 1,713 Common Shares underlying options exercisable within 60 days of March 23, 2026.

(5)	Includes 2,517 Common Shares and 1,879 Common Shares underlying options exercisable within 60 days of March 23, 2026.

(6)	Represents Common Shares underlying options exercisable within 60 days of March 23, 2026.

(7)	Represents Common Shares underlying options exercisable within 60 days of March 23, 2026. The options are held by and for the benefit of Ally Bridge Group. See further discussion on Ally Bridge Group holdings in the “Ownership of Our Common Shares” section above.

(8)	Member of the Audit Committee.

(9)	Member of the Compensation Committee

(10)	Member of the Corporate Governance and Nominating Committee.

(11)	Independent director.

Neil Warma has served as CEO of the Company since January 2024 and as a director of the Company since May 2021. Mr. Warma served as our interim CEO from December 2023 through January 2024. Mr. Warma has been a healthcare entrepreneur for over twenty-five years, having managed and advised numerous biotechnology and pharmaceutical companies across the globe. Previously, Mr. Warma was the President and CEO of Genexine, Inc., a publicly-traded global biopharmaceutical company, for which he also serves as a member of its board of directors. Previously, Mr. Warma served as the General Manager of I-Mab Biopharma U.S., a publicly-traded global biopharmaceutical company from September 2019 until May 2022. Mr. Warma was founder and from 2018 to 2019 served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Previously, Mr. Warma was President and CEO and a member of the board of directors of Opexa Therapeutics, Inc., a publicly-traded biopharmaceutical company from 2008 to 2017. He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions at Novartis AG in Basel, Switzerland. Mr. Warma has served as a director for Genexine Ltd., a public company, and Biotechnology Innovation Organization since March 2021 and November 2020, respectively. Mr. Warma earned a Bachelor of Science degree in Neuroscience from the University of

Table of Contents

Toronto and a Master of Business Administration from York University. We believe Mr. Warma’s experience in the biotechnology industry and with our Company qualifies him to serve on our board of directors.

Neil Cashman has served as CSO and as a director of the Company since May 2004 and June 2010, respectively. Dr. Cashman served as a Professor at the UBC from July 2005 until he became Professor Emeritus as of February 1, 2022, when he became a full-time employee of the Company. He has also served as the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases at UBC from 2005 to 2019. He was also director of the ALS Clinic at Vancouver General Hospital from July 2005 to January 2022. Dr. Cashman earned a Bachelor of Arts degree in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr. Cashman served his residency in neurology with the University of Chicago Hospitals & Clinics. We believe Dr. Cashman’s historical experience with our Company as well as his professional experience qualifies him to serve on our board of directors.

Eugene Williams has served as Chairman since September 2022. He served as Chairman and CEO of the Company from October 2021 to September 2022. Prior thereto, Mr. Williams served as Chairman of the Company since July 2015. Prior, Mr. Williams currently serves as CEO of Autoimmunity BioSolutions (ABS) since November 2024, a preclinical stage biotech developing therapeutics and diagnostics in autoimmune disease, and as the SVP Strategy at Acta Pharmaceuticals since November 2022. Acta is developing small molecule therapies and natural supplements for Alzheimer's Disease. Mr. Williams also served as Chairman and Chief Executive Officer of Akashi (f/k/a DART Therapeutics, Inc.) from June 2010 to January 2014. Previously Mr. Williams was a senior executive at Genzyme, where he had broad management responsibilities in drug development, commercialization, and licensing. Mr. Williams graduated from Harvard College with a Bachelor of Arts degree in Economics and earned a Master of Business Administration from Harvard Business School. We believe Mr. Williams’ experience as our Chief Executive Officer, as well as his experience in the biotechnology industry, qualifies him to serve on our board of directors.

Maggie Shafmaster has served as a director of the Company since September 2021 and as lead independent director of the Company since May 2022. Dr. Shafmaster has over 30 years of experience providing intellectual property and transactional advice to the biotechnology and pharmaceutical industries. Prior to her tenure at ProMIS, Dr. Shafmaster was Vice President and Chief Patent Counsel at Sanofi Pasteur from 2011 to 2014 and Senior Vice President and Chief Patent Counsel at Genzyme Corp. from 2006 to 2011. She has also acted as an expert witness in litigations involving trade secret misappropriation and patent infringement. Dr. Shafmaster earned her Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences, a Juris Doctor from New York Law School, and a Bachelor of Arts in Biology from the University of California Santa Cruz. We believe Dr. Shafmaster’s experience in the biotechnology industry qualifies her to serve on our board of directors.

William Wyman has served as a director of the Company since March 2014. In 1984, Mr. Wyman co-founded Oliver Wyman & Co., a general management consulting firm. Since his retirement from the firm in 1995, Mr. Wyman has served as a director and advisor to nearly two dozen public and private companies in the finance and technology industries. Mr. Wyman has also served as a consultant and owner of Wyman Consulting Associates since 2016. Mr. Wyman has been a member of the board of trustees of Dartmouth Hitchcock Medical Center, Mary Hitchcock Hospital, and the Dartmouth Hitchcock Clinic, and currently serves on the Board Joint Development Committee. He is currently a member of the Board of Trustees of New England College. He served as a director of Allston Trading, LLC, a trading firm, since 2008, and as a member of the board of advisors of several private equity firms since 1995. He has also served on the National Academy of Sciences’ committee on health equity. Mr. Wyman earned a Bachelor of Arts degree in Economics from Colgate University and a Master of Business Administration from Harvard Business School. We believe Mr. Wyman’s experience consulting and serving as a director for a variety of public and private companies qualifies him to serve on our board of directors.

Josh Mandel-Brehm has served as a director of the Company since September 2021. Mr. Mandel-Brehm has served as President and Chief Executive Officer of CAMP4 Therapeutics Corporation since May 2017 and as entrepreneur partner with Polaris Partners. Prior to May 2017, Mr. Mandel-Brehm served in business development for Biogen Corporation from May 2013 to May 2017. He has also been a founder and board member for Vico Therapeutics B.V.

Table of Contents

since October 2019. Mr. Mandel-Brehm earned a Bachelor of Arts degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan. We believe Mr. Mandel-Brehm’s experience in the biotechnology industry qualifies him to serve on our board of directors.

Slanix Alex has served as a director of the Company since October 2025. Dr. Alex joined Ally Bridge Group in 2023 and is the President and Portfolio Manager for the Public Equity strategy. Before joining Ally Bridge Group, Slanix invested in life sciences companies as a founding Partner and Senior Analyst for Tri Locum Partners and previously as an Investment Analyst for Consonance Capital Management. Prior to the buy-side, Slanix worked in sell-side biotechnology equity research at RBC Capital Markets and Credit Suisse. Slanix began his career in strategy consulting at Bionest Partners, advising life sciences companies on business development and commercial strategy. Slanix is a licensed pharmacist and holds a PharmD from St John’s University. We believe Dr. Alex’s experience in capital markets and the biotechnology industry qualifies him to serve on our board of directors.

Family Relationships

There are no family relationships among any of our directors.

Legal Proceedings

There are no material legal proceedings to which any of our directors is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or our subsidiary.

Cease Trade Orders and Bankruptcies

To the knowledge of the Company, no executive officer or proposed director of the Company is, as of the date of this proxy statement, or has been, within the ten years prior to the date of this proxy statement, a director, chief executive officer or chief financial officer of any company (including the Company) that: (i) was subject to an order that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer; or (ii) was subject to an order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.

For the purpose of this paragraph, “order” means: (a) a cease trade order; (b) an order similar to a cease trade order; or (c) an order that denied the relevant company access to any exemption under securities legislation that was in effect for a period of more than 30 consecutive days. No executive officer or proposed director of the Company is, as at the date of this proxy statement, or has been within ten years before the date of this proxy statement, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

Penalties and Sanctions

To the knowledge of the Company no executive officer or proposed director of the Company has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority, or has been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable Shareholder in deciding whether to vote for a proposed director.

Table of Contents

Individual Bankruptcies

To the knowledge of the Company, no executive officer or proposed director of the Company has, within the ten years before the date of this proxy statement, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the officer or proposed director.

Interest of Certain Persons or Companies in Matters to be Acted Upon

To the best of our knowledge, except as otherwise disclosed herein, no person who has been a director or executive officer of the Company at any time since the beginning of the Company’s last completed financial year, nor any proposed nominee for election as a director of the Company, nor any associate or affiliate of the foregoing persons, has any substantial or material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted on at the Meeting other than the election of directors and as set out herein.

Table of Contents

DIRECTOR COMPENSATION

As of December 31, 2025, the Company had eight directors, two of whom were also employees: Neil Warma (CEO) and Neil Cashman (CSO). The remaining six directors were considered independent directors at such time, namely Eugene Williams, our Chairman, and Patrick Kirwin, Josh Mandel-Brehm, Maggie Shafmaster, William Wyman, and Slanix Alex.

Directors who hold positions as executive officers with the Company do not receive additional compensation for their service as directors. Accordingly, Mr. Warma and Dr. Cashman did not receive any additional compensation for their service as directors during the year ended December 31, 2025. For a description of the compensation paid to Mr. Warma, see “Summary Compensation Table for 2025 and 2024,” included herein. Dr. Cashman is not a named executive officer for 2025.

Each member of the Company’s board is entitled to reimbursement for reasonable travel and other expenses incurred in connection with attending board meetings and meetings for any committee on which he or she serves.

Compensation of Directors

The form and amount of director compensation is reviewed annually and as deemed advisable by the Compensation Committee, which shall make recommendations to the board based on such review. The Compensation Committee reviews director compensation on an annual basis to ensure that the Company offers director compensation that is: (i) commensurate with the efforts the Company expects from existing board members; (ii) competitive in the Company’s industry in order that the Company might attract the best possible candidates to assist the Company and its shareholders in a fiduciary capacity; and (iii) aligned with shareholder interests as the Company grows. The board retains the ultimate authority to determine the form and amount of director compensation.

Non-employee Director Compensation Policy

In December 2024, we adopted a new non-employee director compensation policy, designed to enable us to attract and retain, on a long term basis, highly qualified non-employee directors. Under the policy, our non-employee directors are eligible to receive cash retainers (which will be payable quarterly in arrears and prorated for partial years of service) and equity awards as set forth below:

Annual Retainer for board Membership: $40,000 for general availability and participation in meetings and conference calls of our board.


Additional Annual Retainer for Committee Membership
Audit Committee Chair:		15,000
Audit Committee member (other than Chair):		7,500
Compensation Committee Chair:		10,000
Compensation Committee member (other than Chair):		5,000
Nominating and Corporate Governance Committee Chair:		8,000
Nominating and Corporate Governance Committee member (other than Chair):		4,000

In addition, our policy provides that, upon initial election or appointment to our board, each new non-employee director will be granted a one-time grant of a non-statutory stock option to purchase 1,600 Common Shares on the date of such director’s election or appointment to the board (the “Director Initial Award”). The Director Initial Award will vest over three years, with ¼ of the Director Initial Grant vesting on the date of grant and the remaining ¾ of the Director Initial Award vesting in equal monthly installments, subject to the non-employee director’s continued services to the company. On the date of each annual meeting of stockholders of our company, each non-employee director who will continue as a non-employee director following such meeting will be granted an annual award of a non-statutory stock option to purchase 800 Common Shares (the “Director Annual Award”). The Director Annual Award will vest in

Table of Contents

full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director’s continued services to the us. At the discretion of the board, non-employee directors, other than directors receiving the Director Initial Award, may receive a re-stake option award to purchase such amount of Common Shares as determined by the board (the “Director Re-Stake Award”). The Director Re-Stake Award will vest over two years, with 1/3 of the Director Initial Grant vesting on the date of grant and the remaining 2/3 of the Director Re-Stake Grant vesting in equal monthly installments, subject to the non-employee director’s continued services to the company.

At the discretion of the board, such awards are subject to full acceleration vesting upon a Sale Event (as defined in the 2025 Plan). The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any non-employee director for service as a non-employee director in a calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes a non-employee director and $750,000 in any other calendar year. We also reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of our board or any committee thereof. Employee directors receive no additional compensation for their service as a director.

Director Compensation for 2025

The following table sets forth all compensation paid to or earned by each director of the Company during fiscal year 2025.


		Fees Earned
		or			Option				All Other
		Paid in Cash			Awards				Compensation
Name⁽¹⁾		($)⁽¹⁾			($)⁽²⁾⁽³⁾				($)⁽⁴⁾		Total ($)
Patrick Kirwin		$	51,500		$	7,916		$	—		$	59,416
Josh Mandel-Brehm		$	55,500		$	7,916		$	—		$	63,416
Maggie Shafmaster		$	50,000		$	7,916		$	—		$	57,916
Eugene Williams		$	50,000		$	7,916		$	168,750		$	226,666
William Wyman		$	64,000		$	7,916		$	—		$	71,916
Slanix Alex		$	7,717		$	—		$	—		$	7,717

(1)Amounts reported reflect cash fees paid to non-employee directors.

(2)The amounts reported in the Option Awards column reflects aggregate grant date fair value computed in accordance with ASC Topic 718, Compensation — Stock Compensation. These amounts reflect our calculation of the value of these awards at the grant date and do not necessarily correspond to the actual value that may ultimately be realized by the director. Please refer to Note 9 of the Notes to the Audited Consolidated Financial Statements for the year ended December 31, 2025 for additional information regarding share based compensation.

(3) The table below shows the aggregate number of outstanding options held by each of our non-employee directors as of December 31, 2025:


Name		Shares underlying option awards (#)
Patrick Kirwin		1,879
Josh Mandel-Brehm		1,713
Maggie Shafmaster		1,713
Eugene Williams		4,046
William Wyman		1,879
Slanix Alex		499

(4)Includes $168,750 of cash consulting fees paid to Mr. Williams during 2025 pursuant to the Williams Consulting Agreement as described below.

(5)Dr. Alex was appointed on October 22, 2025.

Table of Contents

The Company entered into a strategic services consulting agreement with Mr. Williams on September 12, 2022 (the “Williams Consulting Agreement”). Pursuant to the Williams Consulting Agreement, Mr. Williams served as a consultant and strategic advisor to the board from the period beginning on the effective date of the Williams Consulting Agreement and ending on its third anniversary (the “Consulting Period”). Service in this role counts as service towards the vesting and exercisability of Mr. Williams’ outstanding equity compensation awards from the Company, including awards granted to Mr. Williams in his capacity as an employee prior to his resignation date. In exchange for such consulting services, the Company paid Mr. Williams, in equal monthly installments, a consulting fee of $225,000 per year during the Consulting Period. The Consulting Period ended September 12, 2025, and the Other Compensation paid to Mr. Williams during 2025 reflects his pro rata compensation paid during the portion of the year in which the Williams Consulting Agreement was active.

CORPORATE GOVERNANCE

General

We believe that good corporate governance is important to ensure that our company is managed for the long-term benefit of our shareholders. We periodically review our corporate governance policies and practices and compare them to those suggested by various authorities in corporate governance and the practices of other public companies. As a result, we have adopted policies and procedures that we believe are in the best interests of our company and our shareholders.

Other Public Directorships

Mr. Neil Warma served as an independent director from March 2021 to November 2023 for Genexine Ltd., a public company listed on the Korea Stock Exchange.

Mr. Joshua Mandel-Brehm has served as a director since May 2017 of Camp4 Therapeutics Corp., a public company listed on the Nasdaq Global Exchange.

The remaining current directors are not on a board of directors of any other reporting issuer.

Code of Business Conduct and Ethics

Our board of directors has adopted a Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics applies to all of our employees, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions), agents and representatives, including directors and consultants. The full text of our Code of Business Conduct and Ethics is posted on our website at www.promisneurosciences.com. We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics on our website. The inclusion of our website address in this document does not include or incorporate by reference the information on our website into this document, and you should not consider that information a part of this document.

Removal of Directors

The OBCA provides that our directors may be removed by the affirmative vote of the holders of at least a majority of the votes cast at an annual or special meeting of our shareholders, and that certain vacancies on our board of directors, including a vacancy resulting from an enlargement of our board of directors that is permitted by the OBCA, may be filled by a quorum of our directors. In accordance with the terms of the Articles of the Corporation (as amended, the “articles”), and our general by-laws (as amended, the “by-laws”), we expect that our board of directors will be elected to hold office until the next annual shareholders meeting.

Table of Contents

Recommendation of Director Nominees by Stockholders

Our Bylaws provide for advance notice requirements for nominations for election to the board of directors at any annual or special meeting of shareholders, establishing that notice of a nomination for an annual meeting must be provided not less than 30 nor more than 65 days prior to the date of such meeting, subject to exception, and nomination for a special meeting must be provided not later than the fifteenth (15^th) day following the day on which the first public announcement of the date of the special meeting of shareholders was made, among other things. There have been no material changes to the procedures by which our stockholders may recommend nominees to the board of directors.

Determination of Independence

The independence of our directors is determined under the corporate governance rules of the Nasdaq and Canadian securities laws. The independence rules of Nasdaq include a series of objective tests, including that an “independent” person will not be employed by us and will not be engaged in various types of business dealings with us. In addition, the board of directors is required to make a subjective determination as to each person that no material relationship exists with the Company either directly or as a partner, shareholder or officer of an organization that has a relationship with the Company. It has been determined by the board of directors that five of our directors are independent persons under the independence rules of the Nasdaq and Canadian securities laws: Patrick Kirwin, Josh Mandel-Brehm, Maggie Shafmaster, William Wyman, and Slanix Alex. Neil Warma (Chief Executive Officer) and Neil Cashman, M.D. (Chief Scientific Officer) are the non-independent directors of the Company. Neil Warma is not independent because he is the Company’s CEO. Neil Cashman is not independent because he is the Company’s CSO. Eugene Williams was a party to the Williams Consulting Agreement during the preceding three years pursuant to which he received advisory services fees. Mr. Kirwin will be departing from our Board following the Annual Meeting and we thank him for his service as a director.

Director Candidates and Criteria

Our board of directors is responsible for selecting its own members. The board of directors delegates the selection and nomination process to our corporate governance and nominating committee, with the expectation that other members of the board of directors, and of management, will be requested to take part in the process as appropriate.

Generally, our corporate governance and nominating committee identifies candidates for director nominees in consultation with management, through the use of independent director search firms, through recommendations submitted by shareholders or through such other methods as the corporate governance and nominating committee deems to be helpful to identify candidates. Once candidates have been identified, the corporate governance and nominating committee confirms that the candidates meet the minimum qualifications for director nominees established by the corporate governance and nominating committee. These criteria include the candidate’s personal and professional ethics and integrity, achievement and competence in our field and ability to exercise sound business judgment, skills that are complementary to those of our existing board of directors, ability to assist and support management and make significant contributions to our success, and an understanding of the fiduciary responsibilities that are required of a director and the and the ability to act in the interests of all shareholders.

The corporate governance and nominating committee may gather information about the candidates through meetings from time to time, questionnaires, or background checks to evaluate biographical information and background material relating to potential candidates, and interviews of selected candidates by members of the committee and our board. The corporate governance and nominating committee then meets as a group to discuss and evaluate the qualities and skills of each candidate, both on an individual basis and taking into account the overall composition and needs of our board of directors. Based on the results of the evaluation process, the corporate governance and nominating committee recommends candidates for the board of directors’ approval as director nominees for election to the board of directors.

The board of directors does not believe that limits on the number of consecutive terms a director may serve or on the directors’ ages are appropriate at this stage. Instead, each director’s performance and their continued service is assessed

Table of Contents

by the corporate governance and nominating committee in light of the needs of the board of directors and other relevant factors. The board is aware of the positive impacts of bringing new perspectives to the board of directors, and therefore does occasionally add new members; however, it values continuity on the board of directors and maintaining in-depth knowledge of the Company held by at least one of its members who has a longstanding relationship with the Company.

Shareholders may recommend individuals to our corporate governance and nominating committee for consideration as potential director candidates by providing timely notice and meeting the other requirements set forth in our by-laws, including our advance notice provision, and the rules and regulations of the SEC, applicable Canadian securities laws, and the OBCA. Assuming such requirements have been met, the corporate governance and nominating committee will evaluate shareholder-recommended candidates by following substantially the same process, and applying substantially the same criteria, as it follows for candidates submitted by others. If the board determines to nominate a shareholder-recommended candidate and recommends his or her election, then his or her name will be included in our proxy card for the next annual meeting. Shareholders also have the right under the OBCA, subject to the requirements of section 99 therein, to directly nominate director candidates, without any action or recommendation on the part of the committee or our board of directors. However, any such nominations must comply with the Company’s advance notice by-law (see “Recommendation of Director Nominees by Stockholders”, above).

The company conducts an orientation program for each new director, which generally includes conversations with individual members of management. The orientation is designed to familiarize the new director with the company’s business and strategic plans, key policies and practices, principal officers and management structure, auditing and compliance processes and its code of business conduct and ethics. New directors have access to historical published information about the company, its articles and by-laws, the corporate governance guidelines and the charters of the board of directors’ committees and other relevant information. The corporate governance and nominating committee is responsible for providing materials or briefing sessions for continuing directors on topics that will assist them in discharging their duties. In addition, management makes regular presentations to the board of directors on the main areas of the company’s business and new developments in the industry.

Communication from Shareholders

The board of directors will give appropriate attention to written communications that are submitted by shareholders and will respond if and as appropriate. The chairman of the board of directors is primarily responsible for monitoring communications from shareholders and for providing copies or summaries to the other directors as he considers appropriate.

Communications are forwarded to all directors if they relate to important substantive matters and include suggestions or comments that the chairman of the board of directors considers to be important for the directors to know. In general, communications relating to corporate governance and corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters as to which we receive repetitive or duplicative communications.

Board and Committee Meetings

Our board of directors held 7 meetings during 2025. During 2025, all of the directors then in office attended at least 75% of the aggregate of all meetings of the board of directors and all meetings of the committees of the board of directors on which such director then served. A director’s attendance rate is considered by the corporate governance and nominating committee when making recommendations for re-appointment of the director. Continuing directors and nominees for election as directors in a given year are required to attend the annual meeting of shareholders, barring significant commitments or special circumstances. ProMIS held a 2025 annual meeting of shareholders, as well as a 2025 special meeting of shareholders. All of the 7 then-serving directors attended both of these meetings.

Table of Contents

The following table provides the attendance of each director of the Company with respect to board and committee meetings for the fiscal year ended December 31, 2025:


Name of Director	Attendance at Board of Director Meetings	Attendance at Committee Meetings
Neil Warma	8 of 8	N/A
Neil Cashman	8 of 8	N/A
Slanix Alex	1 of 1	N/A
Eugene Williams	8 of 8	N/A
William Wyman	7 of 8	5 of 6
Patrick Kirwin	8 of 8	4 of 4
Josh Mandel-Brehm	8 of 8	5 of 5
Maggie Shafmaster	8 of 8	1 of 1

*Dr. Alex was appointed on October 22, 2025. There were only 1 meeting during Dr. Alex’s tenure in 2025.

Board Mandate

The Board Charter is attached as Exhibit 1 to the Management Information Circular prepared for the Company’s annual meeting of Shareholders held June 28, 2017, which was SEDAR filed on May 24, 2017 www.sedarplus.ca. A copy of the Board Charter may also be found on the Company’s website at: https://promisneurosciences.com/policies-and-compliance.

Committee Charters

The full text of our audit committee charter, compensation committee charter, and corporate governance and nominating committee charter are posted on the investor relations portion of our website at www.promisneurosciences.com. We do not incorporate the information contained on, or accessible through, our corporate website into this Annual Report, and you should not consider it a part of this Annual Report.

Audit Committee

The audit committee assists the Company’s board of directors in fulfilling its oversight responsibilities relating to financial accounting and reporting process and internal controls for the Company and ensuring the adequacy and effectiveness of the Company’s risk management programs. The audit committee reviews the financial reports and other financial information provided by the Company to regulatory authorities and its shareholders, as well as reviews the Company’s system of internal controls regarding finance and accounting, including auditing, accounting, and financial reporting processes. The audit committee held 4 meetings in 2025.

Table of Contents

Composition of the Audit Committee

As of March 23, 2026, the following are the members of the audit committee:


Name of Member		Independent⁽¹⁾		Financially Literate⁽²⁾
William Wyman		Yes		Yes
Patrick Kirwin ⁽⁴⁾		Yes		Yes
Josh Mandel-Brehm		Yes		Yes

Notes:

(1)A member of the audit committee is independent if he or she meets the independence definitions under both National Instrument 52-110-audit committees and Nasdaq Rule 5605 and has no direct or indirect ‘material relationship’ with the Company. A material relationship is a relationship which could, in the view of the Company’s board of directors, reasonably interfere with the exercise of a member’s independent judgment. Any executive officer of the Company is deemed to have a material relationship with the Company.

(2)A member of the audit committee is financially literate if he or she has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company’s financial statements.

(3)Each member of the audit committee is deemed to be an “audit committee financial expert” and has sufficient knowledge in financial and auditing matters to serve on the audit committee.

(4) Mr. Kirwin will be departing from the board of directors and the audit committee following the Annual Meeting and the Company will appoint a member of its board of directors to the audit committee effective as of such date.

Relevant Education and Experience

Each member of the audit committee has experience relevant to his or her responsibilities as an audit committee member. See “Director Biographies” for a description of the education and experience of each audit committee member.

Audit Committee Oversight

At no time since the commencement of the Company’s most recently completed financial year were any audit committee recommendations to nominate or compensate an external auditor not adopted by the board of directors.

Audit Committee Charter

The board of directors has adopted a written charter for the audit committee, which sets out the audit committee’s purpose, duties and responsibilities. The audit committee’s primary responsibilities are (i) overseeing the integrity of the Company’s financial statements and reviewing the financial reports, the audits thereof, and other financial information provided by the Company to any governmental body or the public and other relevant documents; (ii) recommending the appointment and reviewing and appraising the audit efforts of the Company’s external auditor, overseeing the external auditor’s qualifications and independence and providing an open avenue of communication among the external auditor, financial and senior management and the board of directors; (iii) serving as an external and objective party to oversee and monitor the Company’s financial reporting process and internal controls, the Company’s processes to manage business and financial risk, and its compliance with legal, ethical and regulatory requirements; and (iv) encouraging continuous improvement of, and fostering adherence to, the Company’s policies, procedures and practices at all levels. The audit committee must also review and recommend to the board of directors for approval: (a) the annual audited financial statements; and (b) the Company’s financial statements, MD&As, earnings releases and other public

Table of Contents

disclosures and securities filings to be filed with regulatory bodies, such as securities commissions, prior to filing or prior to the release of earnings. In fulfilling its mandate, the audit committee will also, among other things, (1) be directly responsible for the appointment, compensation, retention and oversight of the work of any external auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company; (2) review and discuss, on an annual basis, with the external auditor all significant relationships they have with the Company to determine their independence and report to the board of directors; (3) review the performance of the external auditor; (4) review the report of the external auditor on the annual audited consolidated financial statements; and (5) perform such other duties as required by the Company’s incorporating statute and applicable securities legislation and policies. The audit committee has unrestricted access to all books and records of the Company and may request any information as it may deem appropriate. It also has the authority to retain and compensate special legal, accounting, financial and other consultants or experts in the performance of its duties.

Compensation Committee

The compensation committee of the board of directors assists the board of directors in fulfilling its oversight responsibilities relating to the recruitment, compensation, evaluation and retention of senior management and other key employees, and in particular the CEO, with the skills and expertise needed to enable the Company to achieve its goals and strategies at competitive compensation and with appropriate performance incentives. The compensation committee held 1 meeting in 2025.

Composition of the compensation committee

As of March 23, 2026, the following are the members of the compensation committee:


Name of Member		Independent⁽¹⁾
Maggie Shafmaster		Yes
William Wyman		Yes

Notes:

(1)A member of the compensation committee is independent if he or she meets the independence definitions under both National Instrument 58-101 and Nasdaq Rule 5605 and has no direct or indirect ‘material relationship’ with the Company. A material relationship is a relationship which could, in the view of the Company’s board of directors, reasonably interfere with the exercise of a member’s independent judgment. Any executive officer of the Company is deemed to have a material relationship with the Company.

Compensation Committee Charter

The board of directors has adopted a written charter for the compensation committee, which sets out the compensation committee’s responsibilities. Its primary responsibilities are (1) reviewing and approving and then recommending to the board of directors salary, bonus, and other benefits, direct or indirect, and any change control packages of the Chief Executive Officer and other members of the senior management team; (2) recommending compensation plans and guidelines to the board; (3) administering the Company’s compensation plans, including stock option plans, outside director compensation plans, and such other compensation plans or structures as are adopted by the Company from time-to-time; (4) with the assistance of management, researching and identifying trends in board of directors and employment compensation and benefits; and (5) with the assistance of management, establishing a periodic review of the Company’s policies in the area of management benefits and perquisites. The compensation committee has also been delegated responsibility for, among other things, (a) providing periodic reports to the board of directors on compensation matters; (b) annually reviewing and making recommendations to the board of directors upon the recommendation of members of senior management with respect to the Company’s overall compensation and benefits philosophies and programs for employees, including base salaries, bonus and any incentive plans, deferred compensation and retirement plans and share purchase or issuance plans including stock options; (c) annually reviewing and approving

Table of Contents

corporate goals and objectives relevant to the Chief Executive Officer’s compensation and evaluating his/her performance in light of those corporate goals and objectives and, based on such analysis, annually reviewing and making recommendations to the board of directors with respect to the Company’s compensation and benefit programs for the Chief Executive Officer and doing the same for other senior officers of the Company including base salaries, bonuses or other performance incentives and stock options; (d) reviewing and approving a report on Executive Compensation on an annual basis in connection with the preparation of materials to be provided to shareholders in connection with the Company’s annual shareholder meeting or as otherwise required pursuant to any applicable securities laws or exchange rules; (e) reviewing all other executive compensation disclosure; and (f) reviewing and recommending to the board of directors the compensation of the board of directors.

Compensation Consultant

Alpine Rewards (“Alpine”) has served as the Compensation Committee’s independent compensation consultant since October 2024. Alpine reports directly to the Compensation Committee, and the Compensation Committee has the sole authority to hire, terminate and direct the work of Alpine. Alpine provides various executive compensation services to the Compensation Committee, including an analysis of executive compensation as relates to base salary, target annual cash incentives and long-term equity incentives for executive officers and advice on evolving industry practices and market information. As part of its engagement, Alpine assists our Compensation Committee in developing an appropriate group of peer companies to help us determine the appropriate level of overall compensation for our executive officers, as well as assess each separate element of compensation, with a goal of ensuring that the compensation we offer to our executive officers is competitive and fair. Alpine also provides the Compensation Committee with advice and analysis regarding compensation of non-employee directors. The Compensation Committee has assessed the independence of Alpine pursuant to SEC and Nasdaq rules and, taking into account the relevant factors for consideration, concluded that the work of Alpine for the Compensation Committee does not raise any conflict of interest.

Corporate Governance and Nominating Committee

The Corporate Governance and Nominating Committee of the board of directors assists the board of directors in fulfilling its oversight responsibilities relating to the corporate governance of the Company and the size, structure, and membership of the board of directors and its committees. The Corporate Governance and Nominating Committee held 1 meeting in 2025.

Composition of the Corporate Governance and Nominating Committee

As of March 23, 2026, the following are the members of the Corporate Governance and Nominating Committee:


Name of Member		Independent⁽¹⁾
Josh Mandel-Brehm		Yes
Patrick Kirwin		Yes
William Wyman		Yes

Notes:

(1)A member of the Corporate Governance and Nominating Committee is independent if he or she meets the independence definitions under both National Instrument 58-101 and Nasdaq Rule 5605 and has no direct or indirect ‘material relationship’ with the Company. A material relationship is a relationship which could, in the view of the Company’s Board, reasonably interfere with the exercise of a member’s independent judgment. Any executive officer of the Company is deemed to have a material relationship with the Company.

Table of Contents

Corporate Governance and Nominating Committee Charter

The board of directors has adopted a written charter for the Corporate Governance and Nominating Committee, which sets out the Corporate Governance and Nominating Committee’s responsibilities. Its primary function is to assist the board of directors in fulfilling its oversight responsibilities by (i) assessing the effectiveness of the board of directors as a whole as well as discussing the contribution of individual members; (ii) assessing the Company’s governance; (iii) proposing new nominees for appointment to the board of directors; and (iv) orienting new directors. The Corporate Governance and Nominating Committee has been delegated responsibility for, among other things, (a) reviewing on a periodic basis, the size and composition of the board of directors and ensuring that an appropriate number of independent directors sit on the board of directors; (b) facilitating the independent functioning and maintaining an effective relationship between the board of directors and management of the Company; (c) annually reviewing the performance and qualifications of existing directors in connection with their re-election; (d) reviewing the quality of the Company’s governance and suggesting changes to the Company’s governance practices to the board of directors as appropriate; (e) establishing qualifications and skills necessary for members of the board of directors (as well as skills and competencies the board of directors needs as a whole) and procedures for identifying possible nominees who meet these criteria (and who are likely to bring to the board of directors the skills and qualifications the board of directors needs as a whole); (f) establishing an appropriate review selection process for new nominees to the board of directors; (g) analyzing the needs of the board of directors when vacancies arise on the board of directors and identifying and recommending nominees who meet such needs; and (h) ensuring that disclosure and securities compliance policies are in place.

Although the Company does not currently have a written policy relating to the identification and nomination of women, Aboriginal peoples, persons with disabilities or members of visible minorities as directors, when the Corporate Governance and Nominating Committee recommends candidates for director positions, it considers not only the qualifications, personal qualities, business background and experience of the candidates, it also considers the composition of the group of nominees, to best bring together a selection of candidates allowing the board of directors to perform efficiently and act in the best interests of the Company and its shareholders. The Company is aware of the benefits of diversity on the board and at the executive and senior management levels, and therefore the level of representation of women, Aboriginal peoples, persons with disabilities and members of visible minorities is one factor taken into consideration during the search process for directors and for executives and senior management positions. The board of directors also considers the composition of the group of directors and senior management, including the representation of women, Aboriginal peoples, persons with disabilities and members of visible minorities, to best bring together a selection of candidates allowing the company’s management to perform efficiently and act in the best interest of the company and its shareholders.

Indemnification Agreements

In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers. The Company currently has directors’ and officers’ insurance.

Policy on Trading, Pledging and Hedging of Company Stock

Certain transactions in our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance risk or could create the appearance of misalignment between management and stockholders. In addition, securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, thus creating the risk that a sale may occur at a time when an

Table of Contents

officer or director is aware of material, non-public information or otherwise is not permitted to trade in Company securities. Our insider trading policy expressly prohibits short sales and derivative transactions of our stock by our executive officers, directors, employees and certain designated persons, including short sales of our securities, buying securities on margin or holding securities in a margin account or purchasing financial instruments to hedge or offset a decrease in the market value of our securities Our insider trading policy expressly prohibits purchases or sales of puts, calls, or put options regarding our securities.

Insider Trading Policy and Procedures

We maintain an insider trading policy governing the purchase, sale and other dispositions of the Company’s securities that applies to all of our directors, officers, employees and other covered persons. We believe that the insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. It is also the policy of the Company to comply with all insider trading laws and regulations. A copy of the Company’s insider trading policy is filed as Exhibit 19.1 to the Company’s Annual Report.

Compensation Committee Interlocks and Insider Participation

Mr. Wyman and Ms. Shafmaster served on the Company compensation committee during 2025. Each member was an independent director while serving on the compensation committee. None of the Company’s executive officers served as a member of the compensation committee (or other board of directors committee performing equivalent functions or, in the absence of any such committee, the entire board of directors) of another entity, one of whose executive officers served as a director of the Company or on the compensation committee, during the fiscal year ended December 31, 2025. None of the Company’s executive officers served as a director of another entity, one of whose executive officers served on the compensation committee, during the fiscal year ended December 31, 2025.

Board Leadership Structure and Risk Oversight

Our board of directors is currently chaired by Eugene Williams. Neil Warma, our chief executive officer is currently on the board of directors and Maggie Shafmaster is our lead independent director. The board of directors has not adopted a position description for the chairperson. However, there is a shared understanding on the board of the chairperson’s responsibilities. The chairperson’s primary role is to provide leadership to the board of directors and its committees, including chairing meetings in a manner that facilitates open discussions and expressions of competing views. The chairperson is also responsible for, among other things, assisting the board of directors in obtaining information required for the performance of their duties, retaining appropriately qualified and independent advisors as needed, working with the board to support board of directors development and to ensure a proper committee structure is in place, providing a link between the board of directors and management and acting in an advisory capacity to the chief executive officer in all matters concerning the interests and management of the company. Our board of directors also believes that this structure ensures a greater role for the non-management directors in the oversight of our company and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our board of directors. Our board of directors believes its administration of its risk oversight function has not affected its leadership structure. The board has not adopted a separate position description for our chief executive officer. The role and responsibilities of the chief executive officer is delineated by frequent discussion and interaction between the board chairperson and the chief executive officer. The board has not adopted a separate position description for the lead independent director. However, there’s a shared understanding on the board of the lead independent director’s responsibilities. The lead independent director is responsible for calling and presiding over separate meetings of the independent directors, presiding over periodic meetings of independent directors, serving as a liaison between the chairperson and the independent directors and performing additional duties as the board may otherwise determine and delegate.

Table of Contents

Oversight of Risk

Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including risks relating to our financial condition, development and activities, operations, strategic direction and intellectual property as more fully discussed under “Risk Factors” in our Annual Report on Form 10-K. Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. The charter of the board of directors specifically includes identification of principal risks of the business and ensuring that appropriate systems are in place to manage such risks, with support of the audit committee, as a duty of the board of directors.

Our board of directors regularly discusses with management our major risk exposures, the potential impact of these risks on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior management to enable our board to understand the company’s risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, cyber, regulatory, strategic and reputational risk.

The audit committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether our compensation policies or programs are appropriate for the size and scope of our Company. The corporate governance and nominating committee manages risks associated with the independence and effectiveness of the board of directors, corporate disclosure practices, and quality of existing governance. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors is regularly informed through committee reports about such risks. Matters of significant strategic risk are considered by our board of directors as a whole.

Conflicts of Interest

Conflicts of interest may arise as a result of the directors and officers of the Company also holding positions as directors or officers of other companies. Some of the individuals that are directors and officers of the Company have been and will continue to be engaged in the identification and evaluation of assets, businesses, and companies on their own behalf and on behalf of other companies, and situations may arise where the directors and officers of the Company will be in direct competition with the Company. Conflicts, if any, will be subject to the procedures and remedies provided under the Company’s Code of Business Conduct and Ethics.

Assessments

The Corporate Governance and Nominating Committee are responsible for conducting annual assessments of the effectiveness of the board, as well as the effectiveness and contribution of each board committee and each individual director. There is no formal assessment procedure.

Table of Contents

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Related Party Transactions

For the Company, a related party transaction includes any transaction or proposed transaction in which:

●

the Company is or will be a participant;

●

the aggregate amount involved exceeds the lesser of $120,000 or $150,000 (approximately 1% of the Company’s average assets for the last two fiscal years) at year end for the last two completed fiscal years; and

●

any related party has or will have a direct or indirect material interest.

Related persons include any person who is or was (since the beginning of the last fiscal year, even if such person does not presently serve in that role) an executive officer or director of the Company, any shareholder beneficially owning more than 5% of any class of the Company’s voting securities or an immediate family member of any such persons. Immediate family member means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, sister-in-law, and any person (other than a tenant or employee) sharing the household of such person.

Pursuant to its charter, the audit committee is charged with oversight over related party transactions entered into by the Company and conducts an appropriate review of all related party transactions for potential conflict of interest situations on an ongoing basis. We do not have a separate related person transaction policy.

Company Transactions with Related Parties

Since January 1, 2024, the Company has entered into related party transactions as included below. For information on agreements with our named executive officers, please see the section entitled “Executive Compensation.”

Neil Cashman. In April 2016, the Company entered into a collaborative research agreement (as amended, the “CRA”) with the University of British Columbia (“UBC”) and the Vancouver Coastal Health Authority in the original amount of C$787,500 with the Company’s Chief Scientific Officer as principal investigator at UBC. In December 2024 funding was increased to an aggregate total of C$5,830,000. During the years ended December 31, 2025 and 2024, the Company made cash payments of $428,860 and $605,645, respectively pursuant to the CRA.

Eugene Williams. On September 12, 2022, the Company entered into a strategic services agreement with Mr. Williams (the “Williams Consulting Agreement”) to provide consulting services to the Company for a period of up to three years. Mr. Williams was paid cash consulting fees of $168,750 and $225,000 related to the Williams Consulting Agreement in 2025 and 2024, respectively. The Williams Consulting Agreement terminated in September 2025.

Transactions with 5% Holders

The following holders beneficially own greater than 5% of any class of the Company’s voting securities.

Entities Affiliated with Janus Henderson

●

In January 2026, in a private offering, Entities affiliated with Janus Henderson acquired 1,292,757 Common Shares, pre-funded warrants to purchase 100,000 Common Shares, and Warrants to purchase 1,392,757 Common Shares for an aggregate purchase price of $14,999,983.

Table of Contents

Entities Affiliated with Ally Bridge Group

●

In January 2026, in a private offering, entities affiliated with Ally Bridge Group acquired 700,741 Common Shares and warrants to purchase 700,741 Common Shares for an aggregate purchase price of $8,499,988.

●

In July 2025, in a private offering, entities affiliated with Ally Bridge Group exercised warrants to purchase 4,899,069 Common Shares and acquired warrants to purchase 7,348,604 Common Shares for an aggregate purchase price of $5,469,468.

●

Slanix Paul Alex, President and Portfolio Manager for Ally Bridge Group's Public Equity strategy, is a member of our board of directors.

Entities Affiliated with Deep Track

●

In January 2026, in a private offering, entities affiliated with Deep Track acquired 835,655 Common Shares and warrants to purchase 835,655 Common Shares for an aggregate purchase price of $9,000,004.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

●

In January 2026, in a private offering, Wellington Biomedical Innovation Master Investors (Cayman) II L.P. acquired 696,378 Common Shares and warrants to purchase 696,378 Common Shares for an aggregate purchase price of $7,499,991.

Trails Edge Biotechnology Master Fund, LP

●

In January 2026, in a private offering, Trails Edge Biotechnology Master Fund, LP acquired 557,103 Common Shares and warrants to purchase 557,103 Common Shares for an aggregate purchase price of $5,999,999.

Entities Affiliated with Great Point

●

In January 2026, in a private offering, entities affiliated with Great Point acquired 371,402 Common Shares and warrants to purchase 371,402 Common Shares for an aggregate purchase price of $4,000,000.

Entities Affiliated with Sphera

●

In January 2026, in a private offering, entities affiliated with Sphera acquired 324,977 Common Shares and warrants to purchase 324,977 Common Shares for an aggregate purchase price of $3,500,002.

Entities Affiliated with Jeremy Sclar

●

In January 2026, in a private offering, entities affiliated with Jeremy Sclar acquired 232,126 Common Shares and warrants to purchase 232,126 Common Shares for an aggregate purchase price of $2,499,997.

●

In July 2025, in a private offering, entities affiliated with Jeremy Sclar exercised warrants to purchase 2,093,022 Common Shares and acquired warrants to purchase 3,139,533 Common Shares for an aggregate purchase price of $2,336,713.

Table of Contents

Woodline Master Fund LP

●

In January 2026, in a private offering, Woodline Master Fund LP acquired 371,402 Common Shares and warrants to purchase 371,402 Common Shares for an aggregate purchase price of $4,000,000.

Shaf QIC, LLC

●

In January 2026, in a private offering, Shaf QIC, LLC acquired 129,990 Common Shares and warrants to purchase 129,990 Common Shares for an aggregate purchase price of $1,399,992.

●

In July 2025, in a private offering, Shaf QIC, LLC exercised warrants to purchase 2,790,699 Common Shares and acquired warrants to purchase 4,186,049 Common Shares for an aggregate purchase price of $784,884.

Squadron Master Fund LP

●

In January 2026, in a private offering, Squadron Master Fund LP acquired 324,977 Common Shares and warrants to purchase 324,977 Common Shares for an aggregate purchase price of $3,500,002.

Indebtedness of Directors and Executive Officers

No directors, proposed nominees for election as directors, executive officers or their respective associates or affiliates, or other management of the Company were indebted to the Company as of the end most recently completed financial year or as at the date hereof.

Interest of Informed Persons in Material Transactions

Management is not aware of any material interest, direct or indirect, of any informed person of the Company any proposed director or any associate or affiliate of any informed person or proposed director in any transaction since the commencement of the Company’s most recently completed financial year, or in any proposed transaction, that has materially affected or would materially affect the Company or any of its affiliates or subsidiaries.

Table of Contents

EXECUTIVE COMPENSATION

The following discussion describes the significant elements of the compensation of the individual who served as the Company’s Chief Executive Officer (“CEO”) during 2025 and the two most highly compensated executive officers other than the CEO during 2025 (collectively, the “named executive officers” or “NEOs”). As of December 31, 2025, the NEOs of the Company were Neil Warma (Director and CEO), Johanne Kaplan (CDO), and Larry Altstiel (CMO).

The Company’s policy with respect to compensation of the named executive officers and other officers of the Company is based upon the principles that total compensation must: (1) be competitive in order to help attract and retain the talent needed to lead and grow the Company’s business; (2) provide a strong incentive for executives and key employees to work towards the achievement of the Company’s goals; and (3) ensure that the interests of management and the Company’s shareholders are aligned.

When determining the compensation of its executive officers, the Compensation Committee considers: (i) recruiting and retaining executives critical to the success of the Company and the enhancement of shareholder value; (ii) providing fair and competitive compensation compared to the remuneration paid by other reporting issuers similarly placed within the same business as the Company; (iii) balancing the interests of management and the Company’s shareholders; and (iv) rewarding performance, both on an individual basis and with respect to operations in general. In order to achieve these objectives, the compensation paid to the Company’s executive officers consists of two components: (i) base salary; and (ii) long-term equity incentives in the form of share options. In making compensation determinations, external sources are consulted when deemed necessary by the Compensation Committee. The members of the Compensation Committee are disclosed under Item 10 of our Annual Report on Form 10-K and elsewhere in this proxy statement.

The total compensation paid to each of the named executive officers of the Company consists of a base salary or consulting fee and share options to reward and retain NEOs. Total compensation paid to each NEO reflects the executive’s overall experience, responsibility and time committed to the organization. The goal of the Company is to pay base salary compensation to retain the NEOs in the range of industry peers, while maintaining the overall goal that total compensation should include long-term components as well.

Each NEO’s base salary is determined after considering the salary levels of other executives with similar responsibilities and experience. Each NEO’s base salary is compared to salary levels of comparable executives at a variety of companies, with particular emphasis on biotechnology companies with similar market capitalizations.

Options are granted by the board to employees, executive officers, including the named executive officers, and directors pursuant to the Company’s Stock Option Plan. The purpose of the Stock Option Plan is to attract, retain and motivate these individuals and create incentives for them to contribute toward the long-term goals of the Company. Moreover, the Stock Option Plan aims to align the interests of participants with the Company’s Shareholders through opportunities of increased equity-based ownership in the Company.

The board may also grant DSUs to senior officers, including any named executive officers, under the Company’s DSU Plan, which provides an alternative form of compensation to satisfy annual and special bonuses payable to senior officers. The number of DSUs granted is determined by dividing the applicable bonus amount by the fair market value of the Common Shares as at the last trading day before calculation in accordance with Nasdaq policies. Recipients of DSUs cannot exercise their DSUs until such time as they cease to be a senior officer at which time they may elect to receive one Common Share for each whole DSU they hold at the time they cease to be eligible to participate in the DSU Share Unit Plan.

Approach to Risk

The board understands that compensation practices can have unintended risk consequences. The Compensation Committee continually reviews the Company’s compensation policies to identify any practice that might encourage an employee to expose the Company to unacceptable risk. At the present time, the Compensation Committee is satisfied

Table of Contents

that the current executive compensation program does not encourage the Company’s executive officers, including the NEOs, to expose the Company to inappropriate risk. The board takes a conservative approach to executive compensation, rewarding individuals for the success of the Company once that success has been demonstrated and encouraging them to continue that success through the grant of long-term incentive awards.

Hedging Policy

There are no specific requirements to prevent an NEO or director from purchasing financial instruments including, for greater certainty, prepaid variable forward contracts, equity swaps, collars, or units of exchange funds that are designed to hedge or offset a decrease in market value of equity securities granted as compensation or held, directly or indirectly, by the NEO or director.

Policies and Practices Regarding Grants of Equity Awards

Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors and our compensation committee periodically reviews the equity incentive compensation of our named executive officers and may grant equity incentive awards to them from time to time. Equity grants may also be made in connection with new hires, promotions or similar events. During 2025, our board of directors and compensation committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards to our executive officers (including our named executive officers), and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

Summary Compensation Table for 2025 and 2024

The following table sets forth all compensation paid to or earned by the named executive officers of the Company in the last two completed fiscal years.


										Option
				Salary			Bonus			Awards			Total
Name and Principal Position		Year		($)			($)			($)⁽¹⁾			($)
Neil Warma CEO		2025		$	500,000		$	104,000		$	226,168		$	830,168
		2024		$	302,244		$	400,000		$	1,612,468		$	2,314,712
Johanne Kaplan Chief Development Officer		2025		$	386,667		$	133,000		$	62,196		$	581,863
Larry Altstiel Chief Medical Officer		2025		$	425,000		$	57,000		$	62,196		$	544,196

(1)

The amounts reported in the Option Awards column reflects aggregate grant date fair value computed in accordance with ASC Topic 718, Compensation - Stock Compensation. These amounts reflect our calculation of the value of these awards at the grant date and do not necessarily correspond to the actual value that may ultimately be realized by the named executive officer. Please refer to Note 9 of the Notes to the Audited Consolidated Financial Statements for the year ended December 31, 2025 for additional information regarding share-based compensation.

Employment Agreements

Neil Warma. In October 2024, Mr. Warma was appointed as the full-time President and CEO of the Company, and in connection with his appointment, the Company and Mr. Warma entered into a revised employment agreement, effective as of October 8, 2024 (the “Warma Employment Agreement”), which superseded the December 30, 2023 employment agreement (the “Original Warma Employment Agreement”). Pursuant to the Warma Employment Agreement, Mr. Warma is paid an annual base salary of $500,000 and annual discretionary bonus with a target of 50%

Table of Contents

of his base salary. In connection with his appointment, Mr. Warma was also granted (i) an option to purchase 45,764 Common Shares (the “Initial Award”) and (ii) an option to purchase 19,613 Common Shares (the “Performance Award”). Per the Company’s 2015 Stock Option Plan, the exercise price of each of the Initial Award and the Performance Award was $28.75 per share. The Initial Award is 25% vested upon grant with the remaining shares vesting ratably over thirty-six months. The Performance Award vests 25% on the date that the 10-day VWAP of the Common Shares on the Nasdaq Capital Market exceeds three times the exercise price, with the remainder vesting ratably over the following thirty-six months. Mr. Warma is also provided (i) severance in the amount of 12-months’ salary, a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a termination without cause and (ii) severance in the amount of the sum of 18-months’ salary and a pro-rated annual bonus at target, acceleration of time-based stock options and standard continuing benefits in connection with a change in control of the Company.

Prior to the Revised Employment Agreement, Mr. Warma was paid an annual base salary of $250,000 and received a one-time incentive cash bonus of $400,000 upon the completion of certain milestones (“Warma Milestones”). In connection with his initial appointment, Mr. Warma was also granted stock options to purchase 8,000 Common Shares (“Warma Employment Options”), which were formally awarded on January 2, 2024 and vested in their entirety upon achievement of the Warma Milestones.

Johanne Kaplan. On September 29, 2025, Dr. Kaplan entered into a revised employment agreement with the Company, effective September 29, 2025 (the “Kaplan Employment Agreement”), which superseded the December 21, 2021 employment agreement (the “Original Kaplan Employment Agreement”). Pursuant to the Kaplan Employment Agreement, Dr. Kaplan is paid an annual base salary of $400,000 and annual discretionary bonus with a target of 35% of her base salary. Also pursuant to the agreement, Dr. Kaplan was also granted an option to purchase 6,600 Common Shares (the “Kaplan Employment Options”). The Kaplan Employment Options vests 25% on the first anniversary of the grant date, with the remaining shares vesting ratably over the following thirty-six months.

Under the Kaplan Employment Agreement, if Dr. Kaplan terminates her employment with the Company for “good reason” or Dr. Kaplan’s employment is terminated by the Company without “cause,” subject to the execution and non-revocation of a release of claims in favor of the Company, Dr. Kaplan will be entitled to receive a severance payment equal to 9 months of her then current base salary, less all applicable taxes and withholdings, paid ratably in accordance with the Company’s regular payroll practices, as well as acceleration of time-based options. Dr. Kaplan will also be entitled to continue receiving group medical coverage pursuant to the COBRA for a period of nine months following her termination, subject to timely election and certain eligibility requirements.

Larry Altstiel. On March 1, 2025, Dr. Altstiel entered into an employment agreement with the Company, effective March 1, 2025 (the “Altstiel Employment Agreement”). Pursuant to the Altstiel Employment Agreement, Dr. Altstiel is paid an annual base salary of $425,000 and annual discretionary bonus with a target of 20% of his base salary. Prior to the Altstiel Employment Agreement, Dr. Altstiel held a consultancy role as a member of the Company’s Scientific Advisory Board beginning February 4, 2022, and then a consultancy role as Chief Medical Officer of the Company beginning April 10, 2022.

Under the Altstiel Employment Agreement, if Dr. Altstiel terminates his employment with the Company for “good reason” or Dr. Altstiel’s employment is terminated by the Company without “cause,” subject to the execution and non-revocation of a release of claims in favor of the Company, Dr. Altstiel will be entitled to receive a severance payment equal to 9 months of his then current base salary, less all applicable taxes and withholdings, paid ratably in accordance with the Company’s regular payroll practices. Dr. Altstiel will also be entitled to continue receiving group medical coverage pursuant to the COBRA for a period of 12 months following his termination, subject to timely election and certain eligibility requirements.

Table of Contents

Outstanding Equity Awards Table for 2025

The following table sets forth outstanding equity awards for the named executive officers of the Company at fiscal 2025 year end.


	Option Awards



				Equity
				Incentive
				Plan
				Awards:
				Number
				of
		Number of	Number of	Securities
		Securities	Securities	Underlying
		Underlying	Underlying	Unexercised		Option
		Unexercised	Unexercised	Unearned		Exercise		Option
		Options (#)	Options (#)	Options		Price		Expiration
		Exercisable	Unexercisable	(#)		($)⁽²⁾		Date
Neil Warma		333	—	—	$	197.22	⁽²⁾	5/14/2031
		8,000	—	—	$	29.25	⁽³⁾	1/2/2034
		24,798	20,966	—	$	28.75	⁽⁴⁾	10/8/2034
		—	—	19,613	$	28.75	⁽⁵⁾	10/8/2034
		—	24,000	—	$	11.25	⁽⁶⁾	9/22/2035
Johanne Kaplan		666	—	—	$	164.35	⁽⁷⁾	7/20/2026
		333

SEC Form DEF 14A filed by ProMIS Neurosciences Inc.